<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680055</article-id><article-id pub-id-type="doi">10.3390/ijms252413418</article-id><article-id pub-id-type="publisher-id">ijms-25-13418</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma&#x02014;A Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-8960-5040</contrib-id><name><surname>Oelschl&#x000e4;ger</surname><given-names>Lorenz</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref><xref rid="fn1-ijms-25-13418" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>K&#x000fc;nstner</surname><given-names>Axel</given-names></name><xref rid="af2-ijms-25-13418" ref-type="aff">2</xref><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref><xref rid="fn1-ijms-25-13418" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Frey</surname><given-names>Friederike</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Leitner</surname><given-names>Theo</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9248-588X</contrib-id><name><surname>Leypoldt</surname><given-names>Lisa</given-names></name><xref rid="af4-ijms-25-13418" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0491-3929</contrib-id><name><surname>Reimer</surname><given-names>Niklas</given-names></name><xref rid="af2-ijms-25-13418" ref-type="aff">2</xref><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0566-4554</contrib-id><name><surname>Gebauer</surname><given-names>Niklas</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1487-9437</contrib-id><name><surname>Bastian</surname><given-names>Lorenz</given-names></name><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref><xref rid="af5-ijms-25-13418" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Weisel</surname><given-names>Katja</given-names></name><xref rid="af4-ijms-25-13418" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Sailer</surname><given-names>Verena-Wilbeth</given-names></name><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref><xref rid="af6-ijms-25-13418" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6989-8002</contrib-id><name><surname>R&#x000f6;cken</surname><given-names>Christoph</given-names></name><xref rid="af7-ijms-25-13418" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Klapper</surname><given-names>Wolfram</given-names></name><xref rid="af7-ijms-25-13418" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Konukiewitz</surname><given-names>Bj&#x000f6;rn</given-names></name><xref rid="af7-ijms-25-13418" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Murga Penas</surname><given-names>Eva Maria</given-names></name><xref rid="af8-ijms-25-13418" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9927-5124</contrib-id><name><surname>Forster</surname><given-names>Michael</given-names></name><xref rid="af9-ijms-25-13418" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Schub</surname><given-names>Natalie</given-names></name><xref rid="af5-ijms-25-13418" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8298-4135</contrib-id><name><surname>Ahmed</surname><given-names>Helal M. M.</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kirfel</surname><given-names>Jutta</given-names></name><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref><xref rid="af6-ijms-25-13418" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>von Bubnoff</surname><given-names>Nikolas Christian Cornelius</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4763-4521</contrib-id><name><surname>Busch</surname><given-names>Hauke</given-names></name><xref rid="af2-ijms-25-13418" ref-type="aff">2</xref><xref rid="af3-ijms-25-13418" ref-type="aff">3</xref><xref rid="fn2-ijms-25-13418" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4655-6269</contrib-id><name><surname>Khandanpour</surname><given-names>Cyrus</given-names></name><xref rid="af1-ijms-25-13418" ref-type="aff">1</xref><xref rid="c1-ijms-25-13418" ref-type="corresp">*</xref><xref rid="fn2-ijms-25-13418" ref-type="author-notes">&#x02021;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tagliaferri</surname><given-names>Pierosandro</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Miricescu</surname><given-names>Daniela</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-25-13418"><label>1</label>Department of Hematology and Oncology, University Medical Center Schleswig-Holstein (UKSH), University Cancer Center Schleswig-Holstein (UCCSH), Campus L&#x000fc;beck, 23538 L&#x000fc;beck, Germany</aff><aff id="af2-ijms-25-13418"><label>2</label>Medical Systems Biology Group, L&#x000fc;beck Institute of Experimental Dermatology, University of L&#x000fc;beck, 23538 L&#x000fc;beck, Germany</aff><aff id="af3-ijms-25-13418"><label>3</label>University Cancer Center Schleswig-Holstein, University Hospital of Schleswig-Holstein, 23538 L&#x000fc;beck, Germany</aff><aff id="af4-ijms-25-13418"><label>4</label>Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20521 Hamburg, Germany</aff><aff id="af5-ijms-25-13418"><label>5</label>Division for Stem Cell Transplantation and Immunotherapy, University Hospital of Schleswig-Holstein, 24105 Kiel, Germany</aff><aff id="af6-ijms-25-13418"><label>6</label>Department of Pathology, University of L&#x000fc;beck, 23538 L&#x000fc;beck, Germany</aff><aff id="af7-ijms-25-13418"><label>7</label>Department of Pathology, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, 24105 Kiel, Germany</aff><aff id="af8-ijms-25-13418"><label>8</label>Institute of Human Genetics, University Hospital Schleswig-Holstein (UKSH)/Christian-Albrechts University Kiel (CAU), 24105 Kiel, Germany</aff><aff id="af9-ijms-25-13418"><label>9</label>Institute of Clinical Molecular Biology, Christian-Albrechts University, 24105 Kiel, Germany</aff><author-notes><corresp id="c1-ijms-25-13418"><label>*</label>Correspondence: <email>cyrus.khandanpour@uksh.de</email></corresp><fn id="fn1-ijms-25-13418"><label>&#x02020;</label><p>These authors contributed equally to this manuscript.</p></fn><fn id="fn2-ijms-25-13418"><label>&#x02021;</label><p>These authors shared senior authorship.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>25</volume><issue>24</issue><elocation-id>13418</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The complex and heterogeneous genomic landscape of multiple myeloma (MM) and many of its clinical and prognostic implications remains to be understood. In other cancers, such as breast cancer, using whole-exome sequencing (WES) and molecular signatures in clinical practice has revolutionized classification, prognostic prediction, and patient management. However, such integration is still in its early stages in MM. In this study, we analyzed WES data from 35 MM patients to identify potential mutational signatures and driver mutations correlated with clinical and cytogenetic characteristics. Our findings confirm the complex mutational spectrum and its impact on previously described ontogenetic and epigenetic pathways. They show TYW1 as a possible new potential driver gene and find no significant associations of mutational signatures with clinical findings. Further studies are needed to strengthen the role of mutational signatures in the clinical context of patients with MM to improve patient management.</p></abstract><kwd-group><kwd>multiple myeloma</kwd><kwd>whole-exome sequencing</kwd><kwd>somatic signatures</kwd></kwd-group><funding-group><award-group><funding-source>OMICS compute cluster at the University of L&#x000fc;beck</funding-source></award-group><award-group><funding-source>BMBF project OUTLIVE-CRC</funding-source><award-id>FKZ 01KD2103A</award-id></award-group><award-group><funding-source>Integrated and Standardized NGS Workflows for Personalized Therapy, Instand-NGS4P</funding-source><award-id>874719</award-id></award-group><funding-statement>A.K., N.R. and H.B. acknowledge computational support from the OMICS compute cluster at the University of L&#x000fc;beck. H.B. and A.K. acknowledge support from the BMBF project OUTLIVE-CRC (FKZ 01KD2103A). M.F. was supported by the EU H2020 grant agreement 874719 (Integrated and Standardized NGS Workflows for Personalized Therapy, Instand-NGS4P).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-25-13418"><title>1. Introduction</title><p>Multiple myeloma (MM) is a malignant B-cell neoplasm with an incidence of 1.78 (95% UI 1.69&#x02013;1.87) per 100,000 and is associated with the Western lifestyle [<xref rid="B1-ijms-25-13418" ref-type="bibr">1</xref>,<xref rid="B2-ijms-25-13418" ref-type="bibr">2</xref>,<xref rid="B3-ijms-25-13418" ref-type="bibr">3</xref>]. MM is often preceded by Monoclonal Gammopathy of Unknown Significance (MGUS) or smoldering multiple myeloma (SMM) and is diagnosed following the International Multiple Myeloma Working Group (IMWG) criteria [<xref rid="B2-ijms-25-13418" ref-type="bibr">2</xref>,<xref rid="B4-ijms-25-13418" ref-type="bibr">4</xref>,<xref rid="B5-ijms-25-13418" ref-type="bibr">5</xref>,<xref rid="B6-ijms-25-13418" ref-type="bibr">6</xref>,<xref rid="B7-ijms-25-13418" ref-type="bibr">7</xref>]. Treatment is currently guided by patient- and disease-specific factors, such as comorbidities as well as high-risk cytogenetics, which have evolved significantly over the past decade, resulting in improved therapy [<xref rid="B8-ijms-25-13418" ref-type="bibr">8</xref>,<xref rid="B9-ijms-25-13418" ref-type="bibr">9</xref>].</p><p>Recent studies have described the genomic landscape of MM and its minimal residual disease (MRD) and showed genomic differences between progressing and stable myeloma precursor states [<xref rid="B10-ijms-25-13418" ref-type="bibr">10</xref>,<xref rid="B11-ijms-25-13418" ref-type="bibr">11</xref>,<xref rid="B12-ijms-25-13418" ref-type="bibr">12</xref>,<xref rid="B13-ijms-25-13418" ref-type="bibr">13</xref>]. With mutational signatures being increasingly analyzed in cancer genomics, the findings may provide insights into cancer biology, prognosis, and even treatment decisions through improved disease classification. Furthermore, a practical guide for analyzing somatic signatures in hematological malignancies has been proposed [<xref rid="B14-ijms-25-13418" ref-type="bibr">14</xref>,<xref rid="B15-ijms-25-13418" ref-type="bibr">15</xref>,<xref rid="B16-ijms-25-13418" ref-type="bibr">16</xref>,<xref rid="B17-ijms-25-13418" ref-type="bibr">17</xref>].</p><p>While previous studies have shown associations between genomic alterations and patient outcomes in MM [<xref rid="B18-ijms-25-13418" ref-type="bibr">18</xref>,<xref rid="B19-ijms-25-13418" ref-type="bibr">19</xref>], further studies are needed to investigate the role of somatic signatures in MM. Here, we evaluate the association of somatic signatures with clinical patient characteristics and progression-free survival (PFS) in a cohort of 35 MM patients using whole-exome sequencing (WES). Our results confirm previously reported affected pathways and show new potential driver genes. Significant associations with biological factors or PFS were not found in our study cohort.</p></sec><sec sec-type="results" id="sec2-ijms-25-13418"><title>2. Results</title><sec id="sec2dot1-ijms-25-13418"><title>2.1. Clinical Characteristics of the Study Group</title><p>This study aims to analyze the clinical and genomic features of patients recently diagnosed with MM using clinical and WES data. A total of 35 patients diagnosed with MM between January 2019 and February 2023 were included in this analysis. The median age at diagnosis was 66.8 years, with 42.9% of the patients being male. The majority of patients received bortezomib-based induction therapy, with 17 out of 31 patients (54.8%) subsequently undergoing autologous hematopoietic stem cell transplantation. At the time of analysis, 5 out of the 35 patients (14.3%) had died. Further patient details are shown in <xref rid="ijms-25-13418-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot2-ijms-25-13418"><title>2.2. Mutational Landscape of Multiple Myeloma Identified by Whole Exome Sequencing</title><p>We reconstructed the multiple myeloma mutational landscape from the whole-exome sequencing of the patients&#x02019; tumor DNA. Due to the unavailability of matching germline DNA, the identified variants were rigorously filtered, as detailed in the Methods section. In total, 6755 single-nucleotide variants (SNVs) were identified, of which 67.8% were missense mutations and 18.3% were nonsense mutations. Additionally, 13.7% of all SNVs were insertions or deletions, with the remaining variants comprising non-stop and splice site mutations (0.1% each). All samples were microsatellite stable (MSS 0%). In total, 3 out of 35 patients exhibited a high homologous recombination deficiency score (HRD-score &#x0003e; 42), and 12 patients had a high BRCAness score (&#x0003e;20). The average tumor mutational burden (TMB) was 5.05 mutations per megabase (median 3.35; range 1.75&#x02013;52.20). Genes mutated in more than a third of the cohort included <italic toggle="yes">LILRA5</italic> (54%), <italic toggle="yes">TYW1</italic> (51%), <italic toggle="yes">KMT2C</italic> (40%), <italic toggle="yes">KMT2D</italic> (40%), <italic toggle="yes">NOTCH1</italic> (34%), and <italic toggle="yes">NOTCH2</italic> (34%). All identified variants with PFAM annotations are detailed in <xref rid="app1-ijms-25-13418" ref-type="app">Supplementary Table S1</xref>.</p></sec><sec id="sec2dot3-ijms-25-13418"><title>2.3. Potential Driver Genes and Affected Pathways</title><p>Identifying potential driver genes in cancer is essential as it offers insights into the underlying molecular mechanisms driving tumorigenesis, informs on potential therapeutic targets, and facilitates the development of personalized treatment strategies to improve patient outcomes. In this study, we employed MutSigCV, a robust computational tool, to identify potential driver genes with high confidence, given its ability to detect significantly mutated genes while minimizing false positives by incorporating patient-specific mutational heterogeneity. Of the 23 potential driver genes (<italic toggle="yes">p</italic> &#x0003c; 0.001), several key driver genes were identified in our cohort, with <italic toggle="yes">TYW1</italic>, <italic toggle="yes">KMT2D</italic>, <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">ARID1A</italic>, and <italic toggle="yes">MED12</italic> mutations being the most prevalent, found in 31&#x02013;51% of patient samples. <italic toggle="yes">TYW1</italic> mutations were most frequent, with three variants of missense mutations (<italic toggle="yes">TYW1</italic> c.G393A (<italic toggle="yes">n</italic> = 9), c.R425 (<italic toggle="yes">n</italic> = 15), and c.W437* (<italic toggle="yes">n</italic> = 1)) with allele frequencies between 0.1 and 0.2261. Additionally, our analysis uncovered other mutations previously documented in MM, present in 20&#x02013;29% of our samples. These include mutations in <italic toggle="yes">NCOR1</italic>, <italic toggle="yes">KDM3A</italic>, <italic toggle="yes">KRAS</italic>, and <italic toggle="yes">NRAS</italic>. We also identified alterations in genes involved in various critical biological processes: <italic toggle="yes">MDC1</italic>, associated with DNA damage response and drug resistance in MM; <italic toggle="yes">DAXX</italic>, involved in chromatin regulation; <italic toggle="yes">GPNMB</italic>, linked to immunosuppression in cancer; and <italic toggle="yes">XK</italic>, which plays a role in hematopoiesis [<xref rid="B20-ijms-25-13418" ref-type="bibr">20</xref>,<xref rid="B21-ijms-25-13418" ref-type="bibr">21</xref>,<xref rid="B22-ijms-25-13418" ref-type="bibr">22</xref>,<xref rid="B23-ijms-25-13418" ref-type="bibr">23</xref>,<xref rid="B24-ijms-25-13418" ref-type="bibr">24</xref>]. In-frame insertions in <italic toggle="yes">KMD3A</italic> were uniquely observed in our study cohort. <italic toggle="yes">KRAS</italic> and <italic toggle="yes">GPNMB</italic> mutations were solely attributed to missense mutations, whereas <italic toggle="yes">FCAMR</italic> and <italic toggle="yes">SUZ12</italic> mutations were caused exclusively by nonsense mutations. Notably, some of the latter genes have not been described previously in the context of MM, highlighting novel avenues for research. All identified potential driver genes are illustrated in <xref rid="ijms-25-13418-f001" ref-type="fig">Figure 1</xref>, and <xref rid="app1-ijms-25-13418" ref-type="app">Supplementary Table S2</xref> shows the complete results from MutSigCV.</p><p>Understanding the oncogenic pathways affected by mutations is crucial for deciphering the mechanisms underlying cancer progression and identifying potential therapeutic targets. With this in mind, we identified pathways influenced by mutations implicated in cancer progression. <xref rid="ijms-25-13418-f002" ref-type="fig">Figure 2</xref> illustrates known oncogenic pathways affected by mutations, showcasing myeloma-typical pathways pivotal for MM pathogenesis, such as <italic toggle="yes">MAPK</italic> [<xref rid="B25-ijms-25-13418" ref-type="bibr">25</xref>,<xref rid="B26-ijms-25-13418" ref-type="bibr">26</xref>,<xref rid="B27-ijms-25-13418" ref-type="bibr">27</xref>], <italic toggle="yes">NOTCH</italic> [<xref rid="B28-ijms-25-13418" ref-type="bibr">28</xref>], <italic toggle="yes">HIPPO</italic> [<xref rid="B29-ijms-25-13418" ref-type="bibr">29</xref>], <italic toggle="yes">WNT</italic> [<xref rid="B30-ijms-25-13418" ref-type="bibr">30</xref>], <italic toggle="yes">IP3K</italic> [<xref rid="B31-ijms-25-13418" ref-type="bibr">31</xref>], <italic toggle="yes">NRF2</italic> [<xref rid="B32-ijms-25-13418" ref-type="bibr">32</xref>], <italic toggle="yes">TGF b</italic>, <italic toggle="yes">MYC</italic>, and <italic toggle="yes">TP53</italic> [<xref rid="B33-ijms-25-13418" ref-type="bibr">33</xref>]. While some pathways were found to be affected with high frequency, especially <italic toggle="yes">RTK-RAS</italic> and <italic toggle="yes">NOTCH</italic> pathways (see <xref rid="ijms-25-13418-f002" ref-type="fig">Figure 2</xref>A), others were only found in two samples (<italic toggle="yes">NRF2</italic>).</p><p>Analyzing somatic interactions is crucial as it unveils the intricate network of genetic interactions driving cancer development and progression, shedding light on potential synergistic or antagonistic relationships between mutated genes. In <xref rid="ijms-25-13418-f003" ref-type="fig">Figure 3</xref>, somatic interactions of genes are displayed. Significant somatic interactions of mutations were found between <italic toggle="yes">FCAMR</italic>/<italic toggle="yes">MED12</italic>, <italic toggle="yes">SUZ12</italic>/<italic toggle="yes">NCOR1</italic>, and <italic toggle="yes">MLIP</italic>/<italic toggle="yes">DAXX</italic> (<italic toggle="yes">p</italic> &#x0003c; 0.01), while others did not frequently co-occur (with blue indicating the exclusivity of mutations and red highlighting the co-occurrence of somatic mutations). The interactions provide further insights into the complex molecular landscape of MM and the interplay between mutated genes.</p></sec><sec id="sec2dot4-ijms-25-13418"><title>2.4. Analysis of Somatic Signatures</title><p>Somatic signatures, which represent distinct patterns of mutations arising from various mutagenic processes, are crucial for understanding the underlying mechanisms of cancer development and progression. Since their first description, they have provided insights into the etiology and chronological evolution of cancers, thus playing an increasingly important role in cancer biology and personalized medicine [<xref rid="B34-ijms-25-13418" ref-type="bibr">34</xref>].</p><p>All 35 samples were analyzed for their association with somatic signatures using the COSMIC single base substitutions catalog [<xref rid="B35-ijms-25-13418" ref-type="bibr">35</xref>] (<xref rid="ijms-25-13418-f004" ref-type="fig">Figure 4</xref>). COSMIC single-base substitutions (SBSs) is a catalog of mutational signatures representing distinct single-nucleotide changes observed in cancer genomes derived from extensive sequencing data across different tumor types. Each SBS signature reflects a unique pattern of mutations linked to specific mutational processes, such as aging, environmental exposures, or DNA repair defects. The most dominant signature identified was single-base substitution 5 (SBS5), with a mean prevalence of 73.2% (s.d. &#x000b1; 14.3), present in all samples. SBS5, like SBS1, is associated with cell aging (e.g., the clock-like accumulation of mutations) and correlates with patient age. However, our cohort showed no significant correlation between the contribution of SBS5 and the age at diagnosis (linear regression; <italic toggle="yes">p</italic> = 0.2840; multiple R<sup>2</sup> = 0.0352). This result was corroborated by modeling age as a non-linear trend using b-splines (<italic toggle="yes">p</italic> = 0.3054; multiple R<sup>2</sup> = 0.0715). Next, we analyzed the impact of somatic signatures on tumor mutational burden (TMB) and homologous recombination deficiency (HRD). TMB was best explained by a linear combination of SBS5, SBS8, SBS9, and SBS-MM1 (stepwise linear regression; <italic toggle="yes">p</italic> = 4 &#x000d7; 10<sup>&#x02212;4</sup>; adjusted R<sup>2</sup> = 0.4145), with SBS5, a mutational signature of unknown etiology, having a significant positive correlation (pSBS5 = 0.008). No associations were found for HRD (stepwise linear regression; best model HRD~SBS9; <italic toggle="yes">p</italic> = 0.0817; adjusted R<sup>2</sup> = 0.0614).</p><p>Further, we investigated the associations between mutations in potential driver genes (as depicted in <xref rid="ijms-25-13418-f001" ref-type="fig">Figure 1</xref>) and the estimated somatic signatures. Two genes, <italic toggle="yes">NCOR1</italic> and <italic toggle="yes">GPNMB</italic>, exhibited a significant relationship (<italic toggle="yes">p</italic> &#x0003c; 0.01) between their mutational status and the proportion of somatic signature SBS9 (<italic toggle="yes">NCOR1</italic>; Wilcoxon test; <italic toggle="yes">p</italic> = 0.0054) and SBS8 (<italic toggle="yes">GPNMB</italic>; <italic toggle="yes">p</italic> = 0.0066). SBS9 is associated with non-canonical genome-wide action of activation-induced deaminase (nc-AID). Nc-AID has previously been shown to occur in earlier chronic lymphoid leukemia (CLL) and is associated with IGVH mutational status. Furthermore, <italic toggle="yes">NCOR1</italic> is known to play a role in B-cell development [<xref rid="B36-ijms-25-13418" ref-type="bibr">36</xref>,<xref rid="B37-ijms-25-13418" ref-type="bibr">37</xref>]. Overall, we identified six genes that showed a significant relationship with the proportions of various somatic signatures (<italic toggle="yes">p</italic> &#x0003c; 0.05), highlighting the complex interplay between specific genetic mutations and mutational patterns. Somatic signatures, association to mutated genes, and biological associations are shown in <xref rid="ijms-25-13418-t002" ref-type="table">Table 2</xref>. These findings underscore the importance of understanding gene-specific contributions to mutational signatures, which could provide more profound insights into the etiology and progression of MM.</p></sec><sec id="sec2dot5-ijms-25-13418"><title>2.5. Correlation of Somatic Signatures, Patient Characteristics, Progression-Free Survival (PFS), and Overall Survival (OS)</title><p>In our patient samples, no significant associations were found between somatic signatures and age (<italic toggle="yes">p</italic> &#x0003e; 0.05). No significant correlations between cytogenetics (del17p, t(4;14), t(14;16), t(14;20), 1p/1q alteration, t(11;14), and hyperdiploid) at diagnosis and somatic signatures were found (<italic toggle="yes">p</italic> &#x0003e; 0.05). We next investigated the impact of certain mutations, tumor mutational burden, and somatic signatures on progression-free and overall survival. First, we tested for the influence of tumor mutational burden on PFS but found no significant relationship (Univariate Cox regression; beta = 0.014; <italic toggle="yes">p</italic> = 0.22) To investigate the connection between tumor mutational burden and overall survival, a Cox regression model was used, including age at diagnosis, sex, and estimated TMB as independent variables. None of the variables showed a significant correlation with overall survival (<italic toggle="yes">p</italic> &#x0003e; 0.05). However, we observe a trend that higher TMB at diagnosis leads to longer overall survival (<xref rid="app1-ijms-25-13418" ref-type="app">Supplementary Figure S2</xref>).</p><p>To assess the clinical impact of somatic signatures, we performed clustering of our patient samples based on clinical data and PFS. Our analysis aimed to determine whether specific somatic signatures were associated with differences in PFS. However, the results indicated that there was no significant correlation between the identified somatic signatures and PFS within our patient cohort. Focusing on the Apolipoprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) mutational signature (SBS2 and SBS13), a known adverse risk factor in MM, no significant differences in PFS were observed between APOBEC-positive and -negative samples (<italic toggle="yes">p</italic> = 0.47). This suggests that, despite the potential biological relevance of somatic signatures, they may not always directly influence clinical outcomes such as PFS in MM. Our data did not show statistically significant differences in PFS or OS for patients with <italic toggle="yes">TYW1</italic> mutations despite their high occurrence. However, we found that mutations in <italic toggle="yes">KRAS</italic> impact PFS with a median PFS of 304 days in patients with a mutation (<italic toggle="yes">n</italic> = 9) and 940 days in patients not carrying a mutation (<italic toggle="yes">n</italic> = 26; <italic toggle="yes">p</italic> = 0.07; <xref rid="ijms-25-13418-f005" ref-type="fig">Figure 5</xref>); the most frequent mutations in <italic toggle="yes">KRAS</italic> were G13D (<italic toggle="yes">n</italic> = 4), followed by Q61H (<italic toggle="yes">n</italic> = 2) and G12A/R/V (each <italic toggle="yes">n</italic> = 1). Furthermore, we investigated the impact of somatic signature and gene mutations on overall survival. While no impact of somatic signatures was found, mutations in <italic toggle="yes">KRAS</italic>, <italic toggle="yes">NCOR1</italic>, <italic toggle="yes">JAK1</italic>, and <italic toggle="yes">CROCC</italic> were associated with dismal overall survival. The OS analysis, as a separate analysis for patients undergoing autologous stem cell transplantation, is shown in <xref rid="app1-ijms-25-13418" ref-type="app">Supplementary Figures S3 and S4</xref>.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-25-13418"><title>3. Discussion</title><p>Our study contributes to the understanding of molecular signatures in MM and adds to the efforts to better understand the implications of genomic alterations in patients with MM. We identified new somatic mutations with high frequency in our cohort (e.g., <italic toggle="yes">TYW1</italic>) with a possible role in pathogenesis and did not find significant correlations of somatic signatures with patient characteristics and clinical outcomes.</p><p>In our cohort, 3 of 35 samples (8.57%) showed a high HRD-score, while 12 of 35 (35%) showed a high BRCAness. Previous studies have investigated the role of HRD in MM and the potential use of Poly(ADP-ribose) polymerase (PARP) inhibitors [<xref rid="B17-ijms-25-13418" ref-type="bibr">17</xref>,<xref rid="B38-ijms-25-13418" ref-type="bibr">38</xref>,<xref rid="B39-ijms-25-13418" ref-type="bibr">39</xref>] since PARP enzymes are involved in DNA damage repair. Bortezomib induces a BRCAness state in myeloma cells and impairs the initiation of homologous recombination DNA repair, which may render myeloma cells sensitive to PARP inhibitors [<xref rid="B40-ijms-25-13418" ref-type="bibr">40</xref>]. Given the relatively high numbers of HRD and BRCAness, these findings support the potential use of PARP inhibitors.</p><p>Intra- and inter-patient genomic heterogeneity has been described in MM patients, as well as variation in potential driver genes [<xref rid="B26-ijms-25-13418" ref-type="bibr">26</xref>,<xref rid="B41-ijms-25-13418" ref-type="bibr">41</xref>,<xref rid="B42-ijms-25-13418" ref-type="bibr">42</xref>]. Our study identified new potential driver genes, including TRNA-YW Synthesizing Protein 1 Homolog (<italic toggle="yes">TYW1</italic>) and Mediator Complex Subunit 12 (<italic toggle="yes">MED12</italic>), and confirmed previously described potential driver genes, e.g., <italic toggle="yes">NRAS</italic>, <italic toggle="yes">KRAS,</italic> and <italic toggle="yes">NOTCH1</italic>.</p><p>Interestingly, <italic toggle="yes">TYW1</italic> mutations were present in 18 patients (51%). <italic toggle="yes">TYW1</italic> is a protein-coding gene related to transfer RNA (tRNA) processing, which has not yet been associated with MM. While previous studies have suggested a role of tRNA in tumorigenesis [<xref rid="B43-ijms-25-13418" ref-type="bibr">43</xref>,<xref rid="B44-ijms-25-13418" ref-type="bibr">44</xref>,<xref rid="B45-ijms-25-13418" ref-type="bibr">45</xref>], to our knowledge, our study is the first to report a high frequency of <italic toggle="yes">TYW1</italic> mutations in MM. All mutations are antecedent (c.G393A) or within the radical S-adenosyl methionine (SAM) domain of <italic toggle="yes">TYW1,</italic> which is involved in tRNA modification. <italic toggle="yes">TYW1</italic>&#x02014;together with six other enzymes (<italic toggle="yes">TYW2-5</italic> and tRNA methyltransferase 5 (<italic toggle="yes">TRMT5</italic>))&#x02014;catalyze stepwise modifications of tRNA<sup>phe</sup> at position 37 [<xref rid="B46-ijms-25-13418" ref-type="bibr">46</xref>]. While the hypomodification of tRNA<sup>phe</sup> by the silencing of TYW2 leads to a ribosome frameshift and poorer outcome in colorectal cancer patients [<xref rid="B45-ijms-25-13418" ref-type="bibr">45</xref>], the role of <italic toggle="yes">TYW1</italic> mutations on tRNA modification, the resulting translational changes, its implications on tumorigenesis, and its role as a possible therapeutic target in MM need to be studied further.</p><p><italic toggle="yes">MED12</italic> plays an important role in the initiation of transcription and was linked to response in multiple cancers through the regulation of <italic toggle="yes">TGF-&#x003b2;</italic> signaling [<xref rid="B47-ijms-25-13418" ref-type="bibr">47</xref>]. <italic toggle="yes">MED12</italic> mutations in the N-terminus were linked to <italic toggle="yes">NOTCH</italic> signaling activation in chronic lymphocytic leukemia, whilst the activation of NOTCH signaling is a promotor of disease progression and forms a supportive microenvironment in MM [<xref rid="B48-ijms-25-13418" ref-type="bibr">48</xref>,<xref rid="B49-ijms-25-13418" ref-type="bibr">49</xref>], therefore likely to play a role in its pathogenesis. Interestingly, in our analysis, only in-frame insertions were found in <italic toggle="yes">KDM3A</italic>, which acts as an epigenetic regulator via the demethylation of downstream targets contributing to myeloma cell survival [<xref rid="B50-ijms-25-13418" ref-type="bibr">50</xref>]. The exact biological effect of these insertions will have to be determined.</p><p>Other sub-forms of <italic toggle="yes">KMT2</italic>/<italic toggle="yes">NOTCH</italic>, as well as <italic toggle="yes">ARID1A</italic>, have been previously described in MM or its precursors [<xref rid="B11-ijms-25-13418" ref-type="bibr">11</xref>,<xref rid="B26-ijms-25-13418" ref-type="bibr">26</xref>,<xref rid="B51-ijms-25-13418" ref-type="bibr">51</xref>,<xref rid="B52-ijms-25-13418" ref-type="bibr">52</xref>]. Both <italic toggle="yes">KMT2D</italic> and <italic toggle="yes">NOTCH1</italic> mutations are present in various cancer types. <italic toggle="yes">ARID1A</italic>, in most cases, acts as a cancer suppressor, while the loss of <italic toggle="yes">ARID1A</italic> leads to increased cell proliferation [<xref rid="B53-ijms-25-13418" ref-type="bibr">53</xref>]. In most samples, the <italic toggle="yes">RTK-RAS</italic>, <italic toggle="yes">NOTCH</italic> pathway, or epigenetic gene regulators were affected by potential driver genes.</p><p>The <italic toggle="yes">PI3K/Akt/mTOR</italic> pathway and its impact on MM cell survival and supporting tumor microenvironment have been described [<xref rid="B31-ijms-25-13418" ref-type="bibr">31</xref>,<xref rid="B54-ijms-25-13418" ref-type="bibr">54</xref>,<xref rid="B55-ijms-25-13418" ref-type="bibr">55</xref>]. Particularly, treatment combination with <italic toggle="yes">PIK3CA</italic> inhibitors led to decreased MM cell survival in vitro [<xref rid="B56-ijms-25-13418" ref-type="bibr">56</xref>,<xref rid="B57-ijms-25-13418" ref-type="bibr">57</xref>]. Other mutations occurring in lower frequencies in our studies, such as <italic toggle="yes">XK</italic>, <italic toggle="yes">TRPV6</italic>, <italic toggle="yes">DAXX</italic>, <italic toggle="yes">DMXL2</italic>, <italic toggle="yes">FCAMR</italic>, and <italic toggle="yes">ERLEC1</italic>, need further investigation to determine their role in MM.</p><p>Interestingly, our study revealed a significant interaction between <italic toggle="yes">NCOR1</italic> and <italic toggle="yes">SUZ12</italic> somatic mutations. While <italic toggle="yes">NCOR1</italic> is a transcriptional regulator by bridging repressive transcription factors with chromatin modifiers involved in T-cell survival and B-cell development [<xref rid="B37-ijms-25-13418" ref-type="bibr">37</xref>,<xref rid="B58-ijms-25-13418" ref-type="bibr">58</xref>], <italic toggle="yes">SUZ12</italic> may be involved in chromatin silencing [<xref rid="B59-ijms-25-13418" ref-type="bibr">59</xref>], indicating possible synergistic effects. Further studies must determine the exact mechanisms of somatic interactions and their putative impact on oncogenesis.</p><p>SBS5 was present in all patient samples. This finding is well in line with the accumulation of cellular damage, mutations, and changing microenvironment during aging and its possible role in cancer development [<xref rid="B60-ijms-25-13418" ref-type="bibr">60</xref>,<xref rid="B61-ijms-25-13418" ref-type="bibr">61</xref>,<xref rid="B62-ijms-25-13418" ref-type="bibr">62</xref>]. While we found no correlation between age and SBS5 in our study, the distribution of SBS5 may differ while the disease evolves from its precursors. Cytogenetic abnormalities in MM have been linked to therapy response and prognosis [<xref rid="B19-ijms-25-13418" ref-type="bibr">19</xref>,<xref rid="B63-ijms-25-13418" ref-type="bibr">63</xref>], and the mutational signature of APOBEC is an adverse risk factor in MM [<xref rid="B15-ijms-25-13418" ref-type="bibr">15</xref>,<xref rid="B16-ijms-25-13418" ref-type="bibr">16</xref>,<xref rid="B64-ijms-25-13418" ref-type="bibr">64</xref>,<xref rid="B65-ijms-25-13418" ref-type="bibr">65</xref>]. In this study, no association was found between somatic signatures and cytogenetic findings/progression-free survival or overall survival. We found no significant association between TMB and progression-free or overall survival.</p><p>Following previous results, [<xref rid="B66-ijms-25-13418" ref-type="bibr">66</xref>] we found dismal progression-free survival in patients with KRAS mutations. With 25.7% percent of our study cohort affected by known pathogenic KRAS mutations (G13D, Q61H, and G12A/R/V), our findings underline the possible therapeutic utilities of targeted KRAS inhibitors in patients with MM.</p><p>A total of four mutations were associated with dismal overall survival (<italic toggle="yes">KRAS</italic>, <italic toggle="yes">NCOR1</italic>, <italic toggle="yes">JAK1,</italic> and <italic toggle="yes">CROCC</italic>). In contrast to our finding, KRAS expression but not KRAS mutational status was associated with adverse outcomes [<xref rid="B67-ijms-25-13418" ref-type="bibr">67</xref>]. The role of the other found mutations on OS in MM is still unclear.</p><p>The findings need to be interpreted in consideration of important limitations of our study. Firstly, our sample size is limited. Although, to our knowledge, no differences in methodology in mutation calling were applied, mutation frequencies may be overestimated in our study, considering frequencies in other publications [<xref rid="B10-ijms-25-13418" ref-type="bibr">10</xref>,<xref rid="B68-ijms-25-13418" ref-type="bibr">68</xref>]. The association between somatic signature, cytogenetics, overall, and progression-free survival might unravel with increasing patient/sample numbers. A recent study developed a new individualized patient outcome prediction model that integrates genomic, clinical, and treatment data [<xref rid="B65-ijms-25-13418" ref-type="bibr">65</xref>], but the small sample size in this study does not allow for a similar approach. We focused on the SBS signature as this includes MM-specific signatures (MM1 and MM2). We emphasize that other types of signatures (double-base substitutions (DBSs) and signature of copy number variations (CN)) exist and may provide further insight into the association between somatic signatures and MM. Secondly, due to a lack of material, a correlation with matching germline DNA was not possible. Thirdly, clonal evolution and molecular changes are observed in the majority of patients as the disease progresses and treatment is applied [<xref rid="B69-ijms-25-13418" ref-type="bibr">69</xref>,<xref rid="B70-ijms-25-13418" ref-type="bibr">70</xref>]. Therefore, somatic signatures change during disease evolution and treatment duration, as previously shown [<xref rid="B71-ijms-25-13418" ref-type="bibr">71</xref>]. Our cohort was treated differently, and the median follow-up was relatively short (median 648 days). This limits our findings concerning outcome parameters such as overall and progression-free survival and underscores the need for prospective studies, repetitive analysis, and the correlation of WES data and clinical outcome to evaluate the role of somatic signatures and clinical outcome parameters in MM.</p><p>In summary, this study validates the heterogeneous genomic landscape and affected pathways in MM in a real-world clinical setting, identifies new mutations, such as <italic toggle="yes">TYW1</italic>, that have not been previously reported in MM, and describes associations of clinical findings and progression-free survival with somatic signatures. The findings presented in this study have to be confirmed in larger cohorts and may ultimately improve classification and patient management in the future.</p></sec><sec sec-type="methods" id="sec4-ijms-25-13418"><title>4. Methods</title><sec id="sec4dot1-ijms-25-13418"><title>4.1. Case Selection, Extraction of Nucleic Acids, and Whole-Exome Sequencing</title><p>Samples from 35 patients with newly diagnosed untreated MM according to the IMWG criteria [<xref rid="B1-ijms-25-13418" ref-type="bibr">1</xref>] were collected, and WES analysis was conducted between December 2022 and February 2023. Patients were retrospectively selected for analysis. Clinical data were obtained from patients&#x02019; medical records, including radiology reports, oncology/hematology reports, and laboratory data from January 2019 to February 2023. The cut-off date for analysis was 28 February 2023, with a median follow-up of 648 days.</p><p>Written informed consent for WES analysis was obtained from all 35 patients. The study was approved by the Institutional Review Board of the University of L&#x000fc;beck (2024-104) and conducted following the Declaration of Helsinki.</p><p>Tumor DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) bone marrow biopsies using the Maxwell FFPE Kit system (Promega, Fitchburg, WI, USA). The quality and quantity of DNA was analyzed using the Qubit system (ThermoFisher, Waltham, MA, USA). Library preparation was carried out using the xGen Exome Hyb Panel v2 (IDT) and the Illumina DNA Prep with Enrichment kit (IDT for Illumina). Sequencing was subsequently performed on the NovaSeq 6000 platform (Illumina, San Diego, CA, USA), with a target sequencing coverage of &#x0003e;400&#x000d7; (tumor).</p></sec><sec id="sec4dot2-ijms-25-13418"><title>4.2. Sequencing Data Processing, Variant Calling, and Filtering</title><p>Raw sequencing data (paired-end fastq files) were mapped to the human reference genome (version GRCh38) and processed using nfcore/sarek (v3.2.3) [<xref rid="B72-ijms-25-13418" ref-type="bibr">72</xref>,<xref rid="B73-ijms-25-13418" ref-type="bibr">73</xref>]. Briefly, sequencing quality was assessed using fastqc (v0.11.9), and low-quality bases/reads were removed utilizing fastp (v0.23.4) [<xref rid="B74-ijms-25-13418" ref-type="bibr">74</xref>]. Next, cleaned reads were mapped to GRCh38 using bwa-mem2 (v2.2.1), and mappings were processed according to GATKs best practices. Variant calling in tumor-only mode was performed using Mutect2 (v4.4.0.0) [<xref rid="B75-ijms-25-13418" ref-type="bibr">75</xref>]; identified variants were left-aligned (GATK v4.2.4.1) [<xref rid="B76-ijms-25-13418" ref-type="bibr">76</xref>] and variants were annotated using Variant Effect Predictor (VEP v110 [<xref rid="B77-ijms-25-13418" ref-type="bibr">77</xref>], GRCh38; adding CADD v1.6 [<xref rid="B78-ijms-25-13418" ref-type="bibr">78</xref>], dbNSFP v4.4c, and gnomAD r3.0 as additional annotations) and annotations were converted into <italic toggle="yes">MAF</italic> format using vcf2maf (v1.6.21) [<xref rid="B79-ijms-25-13418" ref-type="bibr">79</xref>]; coverage was extracted directly from the INFO field in the vcf files.</p><p>Variants outside known coding regions (located in, e.g., intron, UTRs) were removed, and variants with population allele frequency &#x0003e; 0.001 in the GNOMAD or POPFREQ MAX database were discarded, as were variants outside regions defined in the sequencing panel. The top 20 most frequently mutated genes (FLAGS, [<xref rid="B80-ijms-25-13418" ref-type="bibr">80</xref>]) were excluded from further analysis to balance artifact removal with retaining true biological signals; the remaining somatic variants were filtered as follows: a minimum coverage of 50, a minimum alternative allele coverage of 5, and a minimum variant allele frequency of 10%. High-impact variants (CADD score &#x0003e; 20) in tumor suppressors and oncogenes, as defined by Vogelstein et al., [<xref rid="B81-ijms-25-13418" ref-type="bibr">81</xref>], were filtered such that a minimum coverage of 20, a minimum alternative coverage of 4, and a minimum variant allele frequency of 10% was required (see <xref rid="app1-ijms-25-13418" ref-type="app">Supplementary Figure S1</xref>). Genes that mutated more often than expected were identified by applying MutSigCV (v1.41 [<xref rid="B82-ijms-25-13418" ref-type="bibr">82</xref>]), and potential drivers were identified using a <italic toggle="yes">p</italic>-value threshold of &#x0003c;0.001. Somatic signatures on single-base substitutions (SBSs) were estimated using mmsig [<xref rid="B83-ijms-25-13418" ref-type="bibr">83</xref>] (v0.0.0.9000; adjusted for GRCh38) on driver and passenger mutations, and HRD scores were calculated employing the MIRACUM-Pipe (v4.1.0 [<xref rid="B84-ijms-25-13418" ref-type="bibr">84</xref>]). Tumor mutational burden (TMB), BRCAness, and microsatellite stability were calculated using the MIRACUM-Pipe (v4.1.0, MSI-Sensor2).</p></sec><sec id="sec4dot3-ijms-25-13418"><title>4.3. Statistical Analysis</title><p>Unless otherwise specified, the analysis and visualizations were conducted using R (version 4.3.2) with the utilization of the following packages: tidyverse (v2.0.0 [<xref rid="B85-ijms-25-13418" ref-type="bibr">85</xref>]) for data handling; maftools (v2.17.0, [<xref rid="B86-ijms-25-13418" ref-type="bibr">86</xref>]) to summarize, analyze, and visualize variant data; and ComplexHeatmap (v2.16.0) to draw heatmaps.</p><p>Progression-free survival (PFS) was calculated from the date of diagnosis and censored at the time of the last clinical contact. PFS analysis, considering potential prognostic factors, was conducted using the Kaplan&#x02013;Meier method and univariate log-rank test. Furthermore, hazard ratios were determined via a Cox proportional hazards regression model. Overall survival (OS) was calculated from the date of diagnosis using the Kaplan&#x02013;Meier method and univariate log-rank test for comparison. The survival analysis was executed utilizing the R package&#x02019;s survivalAnalysis (0.3.0) and survminer (v0.4.9). Survival probability at a certain time was calculated by applying a contsurvplot (v0.2.1) [<xref rid="B87-ijms-25-13418" ref-type="bibr">87</xref>]. Associations between mutations in potential driver genes and the estimated somatic signatures were investigated using non-parametric testing (Wilcoxon test). Associations between tumor mutational burden and somatic signatures were calculated using step-wise linear regression.</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-25-13418"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ijms252413418/s1">https://www.mdpi.com/article/10.3390/ijms252413418/s1</uri>.</p><supplementary-material id="ijms-25-13418-s001" position="float" content-type="local-data"><media xlink:href="ijms-25-13418-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>F.F. collected the patient clinical data. L.O. and F.F. analyzed the clinical data. A.K., N.R. and H.B. conducted bioinformatic processing, and A.K. performed the statistical analysis. L.O. and A.K. wrote the initial manuscript. C.K. designed this study. T.L., L.L., N.G., L.B., K.W., V.-W.S., C.R., W.K., B.K., E.M.M.P., M.F., N.S., H.M.M.A., J.K. and N.C.C.v.B. done writing&#x02014;review and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of L&#x000fc;beck (2024-104).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>CRAM files have been deposited in the European genome-phenome archive (EGA) under the accession number EGA50000000378. Clinical data are available on request from Cyrus Khandanpour (<email>cyrus.khandanpour@uksh.de</email>).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-25-13418"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkumar</surname><given-names>S.V.</given-names></name>
<name><surname>Dimopoulos</surname><given-names>M.A.</given-names></name>
<name><surname>Palumbo</surname><given-names>A.</given-names></name>
<name><surname>Blade</surname><given-names>J.</given-names></name>
<name><surname>Merlini</surname><given-names>G.</given-names></name>
<name><surname>Mateos</surname><given-names>M.-V.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Hillengass</surname><given-names>J.</given-names></name>
<name><surname>Kastritis</surname><given-names>E.</given-names></name>
<name><surname>Richardson</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>e538</fpage><lpage>e548</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70442-5</pub-id><pub-id pub-id-type="pmid">25439696</pub-id>
</element-citation></ref><ref id="B2-ijms-25-13418"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkumar</surname><given-names>S.V.</given-names></name>
</person-group><article-title>Multiple Myeloma: 2022 Update on Diagnosis, Risk-Stratification and Management</article-title><source>Am. J. Hematol.</source><year>2022</year><volume>97</volume><fpage>1086</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1002/ajh.26590</pub-id><pub-id pub-id-type="pmid">35560063</pub-id>
</element-citation></ref><ref id="B3-ijms-25-13418"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Chan</surname><given-names>S.C.</given-names></name>
<name><surname>Lok</surname><given-names>V.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Lucero-Prisno</surname><given-names>D.E.</given-names></name>
<name><surname>Xu</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.-J.</given-names></name>
<name><surname>Elcarte</surname><given-names>E.</given-names></name>
<name><surname>Withers</surname><given-names>M.</given-names></name>
<name><surname>Wong</surname><given-names>M.C.S.</given-names></name>
</person-group><article-title>The Epidemiological Landscape of Multiple Myeloma: A Global Cancer Registry Estimate of Disease Burden, Risk Factors, and Temporal Trends</article-title><source>Lancet Haematol.</source><year>2022</year><volume>9</volume><fpage>e670</fpage><lpage>e677</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(22)00165-X</pub-id><pub-id pub-id-type="pmid">35843248</pub-id>
</element-citation></ref><ref id="B4-ijms-25-13418"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Kyle</surname><given-names>R.A.</given-names></name>
<name><surname>Pfeiffer</surname><given-names>R.M.</given-names></name>
<name><surname>Katzmann</surname><given-names>J.A.</given-names></name>
<name><surname>Caporaso</surname><given-names>N.E.</given-names></name>
<name><surname>Hayes</surname><given-names>R.B.</given-names></name>
<name><surname>Dispenzieri</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Clark</surname><given-names>R.J.</given-names></name>
<name><surname>Baris</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Monoclonal Gammopathy of Undetermined Significance (MGUS) Consistently Precedes Multiple Myeloma: A Prospective Study</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>5412</fpage><lpage>5417</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-194241</pub-id><pub-id pub-id-type="pmid">19179464</pub-id>
</element-citation></ref><ref id="B5-ijms-25-13418"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>B.M.</given-names></name>
<name><surname>Abadie</surname><given-names>J.</given-names></name>
<name><surname>Verma</surname><given-names>P.</given-names></name>
<name><surname>Howard</surname><given-names>R.S.</given-names></name>
<name><surname>Kuehl</surname><given-names>W.M.</given-names></name>
</person-group><article-title>A Monoclonal Gammopathy Precedes Multiple Myeloma in Most Patients</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>5418</fpage><lpage>5422</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-195008</pub-id><pub-id pub-id-type="pmid">19234139</pub-id>
</element-citation></ref><ref id="B6-ijms-25-13418"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zingone</surname><given-names>A.</given-names></name>
<name><surname>Kuehl</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma</article-title><source>Semin. Hematol.</source><year>2011</year><volume>48</volume><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2010.11.003</pub-id><pub-id pub-id-type="pmid">21232653</pub-id>
</element-citation></ref><ref id="B7-ijms-25-13418"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rajkumar</surname><given-names>S.V.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Mateos</surname><given-names>M.-V.</given-names></name>
</person-group><article-title>Smoldering Multiple Myeloma</article-title><source>Blood</source><year>2015</year><volume>125</volume><fpage>3069</fpage><lpage>3075</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-09-568899</pub-id><pub-id pub-id-type="pmid">25838344</pub-id>
</element-citation></ref><ref id="B8-ijms-25-13418"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palumbo</surname><given-names>A.</given-names></name>
<name><surname>Avet-Loiseau</surname><given-names>H.</given-names></name>
<name><surname>Oliva</surname><given-names>S.</given-names></name>
<name><surname>Lokhorst</surname><given-names>H.M.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>H.</given-names></name>
<name><surname>Rosinol</surname><given-names>L.</given-names></name>
<name><surname>Richardson</surname><given-names>P.</given-names></name>
<name><surname>Caltagirone</surname><given-names>S.</given-names></name>
<name><surname>Lahuerta</surname><given-names>J.J.</given-names></name>
<name><surname>Facon</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>2863</fpage><lpage>2869</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.61.2267</pub-id><pub-id pub-id-type="pmid">26240224</pub-id>
</element-citation></ref><ref id="B9-ijms-25-13418"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Branagan</surname><given-names>A.</given-names></name>
<name><surname>Lei</surname><given-names>M.</given-names></name>
<name><surname>Lou</surname><given-names>U.</given-names></name>
<name><surname>Raje</surname><given-names>N.</given-names></name>
</person-group><article-title>Current Treatment Strategies for Multiple Myeloma</article-title><source>JCO Oncol. Pract.</source><year>2020</year><volume>16</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1200/JOP.19.00244</pub-id><pub-id pub-id-type="pmid">32039665</pub-id>
</element-citation></ref><ref id="B10-ijms-25-13418"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolli</surname><given-names>N.</given-names></name>
<name><surname>Biancon</surname><given-names>G.</given-names></name>
<name><surname>Moarii</surname><given-names>M.</given-names></name>
<name><surname>Gimondi</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>de Philippis</surname><given-names>C.</given-names></name>
<name><surname>Maura</surname><given-names>F.</given-names></name>
<name><surname>Sathiaseelan</surname><given-names>V.</given-names></name>
<name><surname>Tai</surname><given-names>Y.-T.</given-names></name>
<name><surname>Mudie</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Analysis of the Genomic Landscape of Multiple Myeloma Highlights Novel Prognostic Markers and Disease Subgroups</article-title><source>Leukemia</source><year>2018</year><volume>32</volume><fpage>2604</fpage><lpage>2616</lpage><pub-id pub-id-type="doi">10.1038/s41375-018-0037-9</pub-id><pub-id pub-id-type="pmid">29789651</pub-id>
</element-citation></ref><ref id="B11-ijms-25-13418"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oben</surname><given-names>B.</given-names></name>
<name><surname>Froyen</surname><given-names>G.</given-names></name>
<name><surname>Maclachlan</surname><given-names>K.H.</given-names></name>
<name><surname>Leongamornlert</surname><given-names>D.</given-names></name>
<name><surname>Abascal</surname><given-names>F.</given-names></name>
<name><surname>Zheng-Lin</surname><given-names>B.</given-names></name>
<name><surname>Yellapantula</surname><given-names>V.</given-names></name>
<name><surname>Derkach</surname><given-names>A.</given-names></name>
<name><surname>Geerdens</surname><given-names>E.</given-names></name>
<name><surname>Diamond</surname><given-names>B.T.</given-names></name>
<etal/>
</person-group><article-title>Whole-Genome Sequencing Reveals Progressive versus Stable Myeloma Precursor Conditions as Two Distinct Entities</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1861</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22140-0</pub-id><pub-id pub-id-type="pmid">33767199</pub-id>
</element-citation></ref><ref id="B12-ijms-25-13418"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Z&#x000e1;topkov&#x000e1;</surname><given-names>M.</given-names></name>
<name><surname>&#x00160;ev&#x0010d;&#x000ed;kov&#x000e1;</surname><given-names>T.</given-names></name>
<name><surname>Fanfani</surname><given-names>V.</given-names></name>
<name><surname>Chyra</surname><given-names>Z.</given-names></name>
<name><surname>&#x00158;&#x000ed;hov&#x000e1;</surname><given-names>L.</given-names></name>
<name><surname>Bezd&#x0011b;kov&#x000e1;</surname><given-names>R.</given-names></name>
<name><surname>&#x0017d;ihala</surname><given-names>D.</given-names></name>
<name><surname>Growkov&#x000e1;</surname><given-names>K.</given-names></name>
<name><surname>Filipov&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>&#x0010c;ern&#x000e1;</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Mutation Landscape of Multiple Myeloma Measurable Residual Disease: Identification of Targets for Precision Medicine</article-title><source>Blood Adv.</source><year>2022</year><volume>6</volume><fpage>368</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020003876</pub-id><pub-id pub-id-type="pmid">34500459</pub-id>
</element-citation></ref><ref id="B13-ijms-25-13418"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manier</surname><given-names>S.</given-names></name>
<name><surname>Salem</surname><given-names>K.Z.</given-names></name>
<name><surname>Park</surname><given-names>J.</given-names></name>
<name><surname>Landau</surname><given-names>D.A.</given-names></name>
<name><surname>Getz</surname><given-names>G.</given-names></name>
<name><surname>Ghobrial</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Genomic Complexity of Multiple Myeloma and Its Clinical Implications</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>100</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.122</pub-id><pub-id pub-id-type="pmid">27531699</pub-id>
</element-citation></ref><ref id="B14-ijms-25-13418"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davies</surname><given-names>H.</given-names></name>
<name><surname>Morganella</surname><given-names>S.</given-names></name>
<name><surname>Purdie</surname><given-names>C.A.</given-names></name>
<name><surname>Jang</surname><given-names>S.J.</given-names></name>
<name><surname>Borgen</surname><given-names>E.</given-names></name>
<name><surname>Russnes</surname><given-names>H.</given-names></name>
<name><surname>Glodzik</surname><given-names>D.</given-names></name>
<name><surname>Zou</surname><given-names>X.</given-names></name>
<name><surname>Viari</surname><given-names>A.</given-names></name>
<name><surname>Richardson</surname><given-names>A.L.</given-names></name>
<etal/>
</person-group><article-title>Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>4755</fpage><lpage>4762</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1083</pub-id><pub-id pub-id-type="pmid">28904067</pub-id>
</element-citation></ref><ref id="B15-ijms-25-13418"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>B.A.</given-names></name>
<name><surname>Wardell</surname><given-names>C.P.</given-names></name>
<name><surname>Murison</surname><given-names>A.</given-names></name>
<name><surname>Boyle</surname><given-names>E.M.</given-names></name>
<name><surname>Begum</surname><given-names>D.B.</given-names></name>
<name><surname>Dahir</surname><given-names>N.M.</given-names></name>
<name><surname>Proszek</surname><given-names>P.Z.</given-names></name>
<name><surname>Melchor</surname><given-names>L.</given-names></name>
<name><surname>Pawlyn</surname><given-names>C.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.F.</given-names></name>
<etal/>
</person-group><article-title>APOBEC Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6997</fpage><pub-id pub-id-type="doi">10.1038/ncomms7997</pub-id><pub-id pub-id-type="pmid">25904160</pub-id>
</element-citation></ref><ref id="B16-ijms-25-13418"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maura</surname><given-names>F.</given-names></name>
<name><surname>Petljak</surname><given-names>M.</given-names></name>
<name><surname>Lionetti</surname><given-names>M.</given-names></name>
<name><surname>Cifola</surname><given-names>I.</given-names></name>
<name><surname>Liang</surname><given-names>W.</given-names></name>
<name><surname>Pinatel</surname><given-names>E.</given-names></name>
<name><surname>Alexandrov</surname><given-names>L.B.</given-names></name>
<name><surname>Fullam</surname><given-names>A.</given-names></name>
<name><surname>Martincorena</surname><given-names>I.</given-names></name>
<name><surname>Dawson</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Biological and Prognostic Impact of APOBEC-Induced Mutations in the Spectrum of Plasma Cell Dyscrasias and Multiple Myeloma Cell Lines</article-title><source>Leukemia</source><year>2018</year><volume>32</volume><fpage>1043</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.345</pub-id></element-citation></ref><ref id="B17-ijms-25-13418"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maura</surname><given-names>F.</given-names></name>
<name><surname>Degasperi</surname><given-names>A.</given-names></name>
<name><surname>Nadeu</surname><given-names>F.</given-names></name>
<name><surname>Leongamornlert</surname><given-names>D.</given-names></name>
<name><surname>Davies</surname><given-names>H.</given-names></name>
<name><surname>Moore</surname><given-names>L.</given-names></name>
<name><surname>Royo</surname><given-names>R.</given-names></name>
<name><surname>Ziccheddu</surname><given-names>B.</given-names></name>
<name><surname>Puente</surname><given-names>X.S.</given-names></name>
<name><surname>Avet-Loiseau</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>A Practical Guide for Mutational Signature Analysis in Hematological Malignancies</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2969</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11037-8</pub-id><pub-id pub-id-type="pmid">31278357</pub-id>
</element-citation></ref><ref id="B18-ijms-25-13418"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samur</surname><given-names>M.K.</given-names></name>
<name><surname>Aktas Samur</surname><given-names>A.</given-names></name>
<name><surname>Fulciniti</surname><given-names>M.</given-names></name>
<name><surname>Szalat</surname><given-names>R.</given-names></name>
<name><surname>Han</surname><given-names>T.</given-names></name>
<name><surname>Shammas</surname><given-names>M.</given-names></name>
<name><surname>Richardson</surname><given-names>P.</given-names></name>
<name><surname>Magrangeas</surname><given-names>F.</given-names></name>
<name><surname>Minvielle</surname><given-names>S.</given-names></name>
<name><surname>Corre</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>3107</fpage><lpage>3118</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.00461</pub-id><pub-id pub-id-type="pmid">32687451</pub-id>
</element-citation></ref><ref id="B19-ijms-25-13418"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardona-Benavides</surname><given-names>I.J.</given-names></name>
<name><surname>De Ram&#x000f3;n</surname><given-names>C.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>N.C.</given-names></name>
</person-group><article-title>Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>336</elocation-id><pub-id pub-id-type="doi">10.3390/cells10020336</pub-id><pub-id pub-id-type="pmid">33562668</pub-id>
</element-citation></ref><ref id="B20-ijms-25-13418"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dyer</surname><given-names>M.A.</given-names></name>
<name><surname>Qadeer</surname><given-names>Z.A.</given-names></name>
<name><surname>Valle-Garcia</surname><given-names>D.</given-names></name>
<name><surname>Bernstein</surname><given-names>E.</given-names></name>
</person-group><article-title>ATRX and DAXX: Mechanisms and Mutations</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2017</year><volume>7</volume><fpage>a026567</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a026567</pub-id><pub-id pub-id-type="pmid">28062559</pub-id>
</element-citation></ref><ref id="B21-ijms-25-13418"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Thingholm</surname><given-names>T.</given-names></name>
<name><surname>H&#x000f8;jrup</surname><given-names>P.</given-names></name>
<name><surname>R&#x000f6;nnstrand</surname><given-names>L.</given-names></name>
</person-group><article-title>XK-Related Protein 5 (XKR5) Is a Novel Negative Regulator of KIT/D816V-Mediated Transformation</article-title><source>Oncogenesis</source><year>2018</year><volume>7</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1038/s41389-018-0057-3</pub-id><pub-id pub-id-type="pmid">29910466</pub-id>
</element-citation></ref><ref id="B22-ijms-25-13418"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruff</surname><given-names>S.E.</given-names></name>
<name><surname>Logan</surname><given-names>S.K.</given-names></name>
<name><surname>Garabedian</surname><given-names>M.J.</given-names></name>
<name><surname>Huang</surname><given-names>T.T.</given-names></name>
</person-group><article-title>Roles for MDC1 in Cancer Development and Treatment</article-title><source>DNA Repair</source><year>2020</year><volume>95</volume><fpage>102948</fpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2020.102948</pub-id><pub-id pub-id-type="pmid">32866776</pub-id>
</element-citation></ref><ref id="B23-ijms-25-13418"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lazaratos</surname><given-names>A.-M.</given-names></name>
<name><surname>Annis</surname><given-names>M.G.</given-names></name>
<name><surname>Siegel</surname><given-names>P.M.</given-names></name>
</person-group><article-title>GPNMB: A Potent Inducer of Immunosuppression in Cancer</article-title><source>Oncogene</source><year>2022</year><volume>41</volume><fpage>4573</fpage><lpage>4590</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02443-2</pub-id><pub-id pub-id-type="pmid">36050467</pub-id>
</element-citation></ref><ref id="B24-ijms-25-13418"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Peng</surname><given-names>Z.</given-names></name>
<name><surname>Hu</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Deacetylation Induced Nuclear Condensation of HP1&#x003b3; Promotes Multiple Myeloma Drug Resistance</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1290</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37013-x</pub-id><pub-id pub-id-type="pmid">36894562</pub-id>
</element-citation></ref><ref id="B25-ijms-25-13418"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>M.A.</given-names></name>
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Keats</surname><given-names>J.J.</given-names></name>
<name><surname>Cibulskis</surname><given-names>K.</given-names></name>
<name><surname>Sougnez</surname><given-names>C.</given-names></name>
<name><surname>Schinzel</surname><given-names>A.C.</given-names></name>
<name><surname>Harview</surname><given-names>C.L.</given-names></name>
<name><surname>Brunet</surname><given-names>J.-P.</given-names></name>
<name><surname>Ahmann</surname><given-names>G.J.</given-names></name>
<name><surname>Adli</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Initial Genome Sequencing and Analysis of Multiple Myeloma</article-title><source>Nature</source><year>2011</year><volume>471</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/nature09837</pub-id><pub-id pub-id-type="pmid">21430775</pub-id>
</element-citation></ref><ref id="B26-ijms-25-13418"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lohr</surname><given-names>J.G.</given-names></name>
<name><surname>Stojanov</surname><given-names>P.</given-names></name>
<name><surname>Carter</surname><given-names>S.L.</given-names></name>
<name><surname>Cruz-Gordillo</surname><given-names>P.</given-names></name>
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Auclair</surname><given-names>D.</given-names></name>
<name><surname>Sougnez</surname><given-names>C.</given-names></name>
<name><surname>Knoechel</surname><given-names>B.</given-names></name>
<name><surname>Gould</surname><given-names>J.</given-names></name>
<name><surname>Saksena</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.12.015</pub-id><pub-id pub-id-type="pmid">24434212</pub-id>
</element-citation></ref><ref id="B27-ijms-25-13418"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kort&#x000fc;m</surname><given-names>K.M.</given-names></name>
<name><surname>Mai</surname><given-names>E.K.</given-names></name>
<name><surname>Hanafiah</surname><given-names>N.H.</given-names></name>
<name><surname>Shi</surname><given-names>C.-X.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.-X.</given-names></name>
<name><surname>Bruins</surname><given-names>L.</given-names></name>
<name><surname>Barrio</surname><given-names>S.</given-names></name>
<name><surname>Jedlowski</surname><given-names>P.</given-names></name>
<name><surname>Merz</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Targeted Sequencing of Refractory Myeloma Reveals a High Incidence of Mutations in CRBN and Ras Pathway Genes</article-title><source>Blood</source><year>2016</year><volume>128</volume><fpage>1226</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-02-698092</pub-id><pub-id pub-id-type="pmid">27458004</pub-id>
</element-citation></ref><ref id="B28-ijms-25-13418"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabol</surname><given-names>H.M.</given-names></name>
<name><surname>Delgado-Calle</surname><given-names>J.</given-names></name>
</person-group><article-title>The Multifunctional Role of Notch Signaling in Multiple Myeloma</article-title><source>J. Cancer Metastasis Treat.</source><year>2021</year><volume>7</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.20517/2394-4722.2021.35</pub-id><pub-id pub-id-type="pmid">34778567</pub-id>
</element-citation></ref><ref id="B29-ijms-25-13418"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyriazoglou</surname><given-names>A.</given-names></name>
<name><surname>Ntanasis-Stathopoulos</surname><given-names>I.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<name><surname>Fotiou</surname><given-names>D.</given-names></name>
<name><surname>Kastritis</surname><given-names>E.</given-names></name>
<name><surname>Dimopoulos</surname><given-names>M.A.</given-names></name>
<name><surname>Gavriatopoulou</surname><given-names>M.</given-names></name>
</person-group><article-title>Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease</article-title><source>Clin. Lymphoma Myeloma Leuk.</source><year>2020</year><volume>20</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.clml.2019.09.620</pub-id><pub-id pub-id-type="pmid">31734019</pub-id>
</element-citation></ref><ref id="B30-ijms-25-13418"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spaan</surname><given-names>I.</given-names></name>
<name><surname>Raymakers</surname><given-names>R.A.</given-names></name>
<name><surname>Van De Stolpe</surname><given-names>A.</given-names></name>
<name><surname>Peperzak</surname><given-names>V.</given-names></name>
</person-group><article-title>Wnt Signaling in Multiple Myeloma: A Central Player in Disease with Therapeutic Potential</article-title><source>J. Hematol. Oncol.</source><year>2018</year><volume>11</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s13045-018-0615-3</pub-id><pub-id pub-id-type="pmid">29776381</pub-id>
</element-citation></ref><ref id="B31-ijms-25-13418"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramakrishnan</surname><given-names>V.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>PI3K/AKT/mTOR Pathway in Multiple Myeloma: From Basic Biology to Clinical Promise</article-title><source>Leuk. Lymphoma</source><year>2018</year><volume>59</volume><fpage>2524</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.1080/10428194.2017.1421760</pub-id><pub-id pub-id-type="pmid">29322846</pub-id>
</element-citation></ref><ref id="B32-ijms-25-13418"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yen</surname><given-names>C.-H.</given-names></name>
<name><surname>Hsu</surname><given-names>C.-M.</given-names></name>
<name><surname>Hsiao</surname><given-names>S.Y.</given-names></name>
<name><surname>Hsiao</surname><given-names>H.-H.</given-names></name>
</person-group><article-title>Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>6723</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21186723</pub-id><pub-id pub-id-type="pmid">32937821</pub-id>
</element-citation></ref><ref id="B33-ijms-25-13418"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>P.</given-names></name>
<name><surname>Qu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Chu</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>T.</given-names></name>
<name><surname>Qian</surname><given-names>Z.</given-names></name>
</person-group><article-title>Pathogenesis and Treatment of Multiple Myeloma</article-title><source>MedComm</source><year>2022</year><volume>3</volume><fpage>e146</fpage><pub-id pub-id-type="doi">10.1002/mco2.146</pub-id><pub-id pub-id-type="pmid">35665368</pub-id>
</element-citation></ref><ref id="B34-ijms-25-13418"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexandrov</surname><given-names>L.B.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Haradhvala</surname><given-names>N.J.</given-names></name>
<name><surname>Huang</surname><given-names>M.N.</given-names></name>
<name><surname>Tian Ng</surname><given-names>A.W.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Boot</surname><given-names>A.</given-names></name>
<name><surname>Covington</surname><given-names>K.R.</given-names></name>
<name><surname>Gordenin</surname><given-names>D.A.</given-names></name>
<name><surname>Bergstrom</surname><given-names>E.N.</given-names></name>
<etal/>
</person-group><article-title>The Repertoire of Mutational Signatures in Human Cancer</article-title><source>Nature</source><year>2020</year><volume>578</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmid">32025018</pub-id>
</element-citation></ref><ref id="B35-ijms-25-13418"><label>35.</label><element-citation publication-type="webpage"><article-title>COSMIC|SBS&#x02014;Mutational Signatures</article-title><comment>Available online: <ext-link xlink:href="https://cancer.sanger.ac.uk/signatures/sbs/" ext-link-type="uri">https://cancer.sanger.ac.uk/signatures/sbs/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-21">(accessed on 21 February 2024)</date-in-citation></element-citation></ref><ref id="B36-ijms-25-13418"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kasar</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Improgo</surname><given-names>R.</given-names></name>
<name><surname>Tiao</surname><given-names>G.</given-names></name>
<name><surname>Polak</surname><given-names>P.</given-names></name>
<name><surname>Haradhvala</surname><given-names>N.</given-names></name>
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Kiezun</surname><given-names>A.</given-names></name>
<name><surname>Fernandes</surname><given-names>S.M.</given-names></name>
<name><surname>Bahl</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Whole-Genome Sequencing Reveals Activation-Induced Cytidine Deaminase Signatures during Indolent Chronic Lymphocytic Leukaemia Evolution</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8866</fpage><pub-id pub-id-type="doi">10.1038/ncomms9866</pub-id><pub-id pub-id-type="pmid">26638776</pub-id>
</element-citation></ref><ref id="B37-ijms-25-13418"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>R.D.</given-names></name>
<name><surname>Knutson</surname><given-names>T.P.</given-names></name>
<name><surname>Munro</surname><given-names>S.A.</given-names></name>
<name><surname>Miller</surname><given-names>J.T.</given-names></name>
<name><surname>Heltemes-Harris</surname><given-names>L.M.</given-names></name>
<name><surname>Mullighan</surname><given-names>C.G.</given-names></name>
<name><surname>Jepsen</surname><given-names>K.</given-names></name>
<name><surname>Farrar</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Nuclear Corepressors NCOR1/NCOR2 Regulate B Cell Development, Maintain Genomic Integrity and Prevent Transformation</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>1763</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01343-7</pub-id><pub-id pub-id-type="pmid">36316474</pub-id>
</element-citation></ref><ref id="B38-ijms-25-13418"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pawlyn</surname><given-names>C.</given-names></name>
<name><surname>Loehr</surname><given-names>A.</given-names></name>
<name><surname>Ashby</surname><given-names>C.</given-names></name>
<name><surname>Tytarenko</surname><given-names>R.</given-names></name>
<name><surname>Deshpande</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Fedorchak</surname><given-names>K.</given-names></name>
<name><surname>Mughal</surname><given-names>T.</given-names></name>
<name><surname>Davies</surname><given-names>F.E.</given-names></name>
<name><surname>Walker</surname><given-names>B.A.</given-names></name>
<etal/>
</person-group><article-title>Loss of Heterozygosity as a Marker of Homologous Repair Deficiency in Multiple Myeloma: A Role for PARP Inhibition?</article-title><source>Leukemia</source><year>2018</year><volume>32</volume><fpage>1561</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1038/s41375-018-0017-0</pub-id><pub-id pub-id-type="pmid">29467487</pub-id>
</element-citation></ref><ref id="B39-ijms-25-13418"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>H.-Y.</given-names></name>
<name><surname>Tang</surname><given-names>H.-L.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.-H.</given-names></name>
<name><surname>Feng</surname><given-names>J.</given-names></name>
<name><surname>Dong</surname><given-names>B.-X.</given-names></name>
<name><surname>Chen</surname><given-names>X.-Q.</given-names></name>
</person-group><article-title>The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects</article-title><source>J. Oncol.</source><year>2022</year><volume>2022</volume><fpage>2800488</fpage><pub-id pub-id-type="doi">10.1155/2022/2800488</pub-id><pub-id pub-id-type="pmid">35422863</pub-id>
</element-citation></ref><ref id="B40-ijms-25-13418"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neri</surname><given-names>P.</given-names></name>
<name><surname>Ren</surname><given-names>L.</given-names></name>
<name><surname>Gratton</surname><given-names>K.</given-names></name>
<name><surname>Stebner</surname><given-names>E.</given-names></name>
<name><surname>Johnson</surname><given-names>J.</given-names></name>
<name><surname>Klimowicz</surname><given-names>A.</given-names></name>
<name><surname>Duggan</surname><given-names>P.</given-names></name>
<name><surname>Tassone</surname><given-names>P.</given-names></name>
<name><surname>Mansoor</surname><given-names>A.</given-names></name>
<name><surname>Stewart</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Bortezomib-Induced &#x0201c;BRCAness&#x0201d; Sensitizes Multiple Myeloma Cells to PARP Inhibitors</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>6368</fpage><lpage>6379</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-06-363911</pub-id><pub-id pub-id-type="pmid">21917757</pub-id>
</element-citation></ref><ref id="B41-ijms-25-13418"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rasche</surname><given-names>L.</given-names></name>
<name><surname>Chavan</surname><given-names>S.S.</given-names></name>
<name><surname>Stephens</surname><given-names>O.W.</given-names></name>
<name><surname>Patel</surname><given-names>P.H.</given-names></name>
<name><surname>Tytarenko</surname><given-names>R.</given-names></name>
<name><surname>Ashby</surname><given-names>C.</given-names></name>
<name><surname>Bauer</surname><given-names>M.</given-names></name>
<name><surname>Stein</surname><given-names>C.</given-names></name>
<name><surname>Deshpande</surname><given-names>S.</given-names></name>
<name><surname>Wardell</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Spatial Genomic Heterogeneity in Multiple Myeloma Revealed by Multi-Region Sequencing</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>268</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00296-y</pub-id><pub-id pub-id-type="pmid">28814763</pub-id>
</element-citation></ref><ref id="B42-ijms-25-13418"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>B.A.</given-names></name>
<name><surname>Mavrommatis</surname><given-names>K.</given-names></name>
<name><surname>Wardell</surname><given-names>C.P.</given-names></name>
<name><surname>Ashby</surname><given-names>T.C.</given-names></name>
<name><surname>Bauer</surname><given-names>M.</given-names></name>
<name><surname>Davies</surname><given-names>F.E.</given-names></name>
<name><surname>Rosenthal</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Hoering</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-03-840132</pub-id><pub-id pub-id-type="pmid">29884741</pub-id>
</element-citation></ref><ref id="B43-ijms-25-13418"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>B.</given-names></name>
<name><surname>Xiong</surname><given-names>Z.</given-names></name>
<name><surname>Shu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Xiong</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
</person-group><article-title>The Dysregulation of tRNAs and tRNA Derivatives in Cancer</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2018</year><volume>37</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s13046-018-0745-z</pub-id><pub-id pub-id-type="pmid">29743091</pub-id>
</element-citation></ref><ref id="B44-ijms-25-13418"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>M.</given-names></name>
<name><surname>Fidalgo</surname><given-names>A.</given-names></name>
<name><surname>Varanda</surname><given-names>A.S.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.</given-names></name>
<name><surname>Santos</surname><given-names>M.A.S.</given-names></name>
</person-group><article-title>tRNA Deregulation and Its Consequences in Cancer</article-title><source>Trends Mol. Med.</source><year>2019</year><volume>25</volume><fpage>853</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2019.05.011</pub-id><pub-id pub-id-type="pmid">31248782</pub-id>
</element-citation></ref><ref id="B45-ijms-25-13418"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossell&#x000f3;-Tortella</surname><given-names>M.</given-names></name>
<name><surname>Llin&#x000e0;s-Arias</surname><given-names>P.</given-names></name>
<name><surname>Sakaguchi</surname><given-names>Y.</given-names></name>
<name><surname>Miyauchi</surname><given-names>K.</given-names></name>
<name><surname>Davalos</surname><given-names>V.</given-names></name>
<name><surname>Setien</surname><given-names>F.</given-names></name>
<name><surname>Calleja-Cervantes</surname><given-names>M.E.</given-names></name>
<name><surname>Pi&#x000f1;eyro</surname><given-names>D.</given-names></name>
<name><surname>Mart&#x000ed;nez-G&#x000f3;mez</surname><given-names>J.</given-names></name>
<name><surname>Guil</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Epigenetic Loss of the Transfer RNA-Modifying Enzyme TYW2 Induces Ribosome Frameshifts in Colon Cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>20785</fpage><lpage>20793</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003358117</pub-id><pub-id pub-id-type="pmid">32778592</pub-id>
</element-citation></ref><ref id="B46-ijms-25-13418"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landgraf</surname><given-names>B.J.</given-names></name>
<name><surname>McCarthy</surname><given-names>E.L.</given-names></name>
<name><surname>Booker</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Radical <italic toggle="yes">S</italic>-Adenosylmethionine Enzymes in Human Health and Disease</article-title><source>Annu. Rev. Biochem.</source><year>2016</year><volume>85</volume><fpage>485</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035504</pub-id><pub-id pub-id-type="pmid">27145839</pub-id>
</element-citation></ref><ref id="B47-ijms-25-13418"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>H&#x000f6;lzel</surname><given-names>M.</given-names></name>
<name><surname>Knijnenburg</surname><given-names>T.</given-names></name>
<name><surname>Schlicker</surname><given-names>A.</given-names></name>
<name><surname>Roepman</surname><given-names>P.</given-names></name>
<name><surname>McDermott</surname><given-names>U.</given-names></name>
<name><surname>Garnett</surname><given-names>M.</given-names></name>
<name><surname>Grernrum</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Prahallad</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-&#x003b2; Receptor Signaling</article-title><source>Cell</source><year>2012</year><volume>151</volume><fpage>937</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.10.035</pub-id><pub-id pub-id-type="pmid">23178117</pub-id>
</element-citation></ref><ref id="B48-ijms-25-13418"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>B.</given-names></name>
<name><surname>S&#x00142;abicki</surname><given-names>M.</given-names></name>
<name><surname>Sellner</surname><given-names>L.</given-names></name>
<name><surname>Dietrich</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Jethwa</surname><given-names>A.</given-names></name>
<name><surname>H&#x000fc;llein</surname><given-names>J.</given-names></name>
<name><surname>Walther</surname><given-names>T.</given-names></name>
<name><surname>Wagner</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes"><sc>MED</sc> 12</italic> Mutations and <sc>NOTCH</sc> Signalling in Chronic Lymphocytic Leukaemia</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>179</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1111/bjh.14869</pub-id><pub-id pub-id-type="pmid">28771672</pub-id>
</element-citation></ref><ref id="B49-ijms-25-13418"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>M.</given-names></name>
<name><surname>Galletti</surname><given-names>S.</given-names></name>
<name><surname>Garavelli</surname><given-names>S.</given-names></name>
<name><surname>Platonova</surname><given-names>N.</given-names></name>
<name><surname>Paoli</surname><given-names>A.</given-names></name>
<name><surname>Basile</surname><given-names>A.</given-names></name>
<name><surname>Taiana</surname><given-names>E.</given-names></name>
<name><surname>Neri</surname><given-names>A.</given-names></name>
<name><surname>Chiaramonte</surname><given-names>R.</given-names></name>
</person-group><article-title>Notch Signaling Deregulation in Multiple Myeloma: A Rational Molecular Target</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>26826</fpage><lpage>26840</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5025</pub-id><pub-id pub-id-type="pmid">26308486</pub-id>
</element-citation></ref><ref id="B50-ijms-25-13418"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohguchi</surname><given-names>H.</given-names></name>
<name><surname>Hideshima</surname><given-names>T.</given-names></name>
<name><surname>Bhasin</surname><given-names>M.K.</given-names></name>
<name><surname>Gorgun</surname><given-names>G.T.</given-names></name>
<name><surname>Santo</surname><given-names>L.</given-names></name>
<name><surname>Cea</surname><given-names>M.</given-names></name>
<name><surname>Samur</surname><given-names>M.K.</given-names></name>
<name><surname>Mimura</surname><given-names>N.</given-names></name>
<name><surname>Suzuki</surname><given-names>R.</given-names></name>
<name><surname>Tai</surname><given-names>Y.-T.</given-names></name>
<etal/>
</person-group><article-title>The KDM3A&#x02013;KLF2&#x02013;IRF4 Axis Maintains Myeloma Cell Survival</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>10258</fpage><pub-id pub-id-type="doi">10.1038/ncomms10258</pub-id><pub-id pub-id-type="pmid">26728187</pub-id>
</element-citation></ref><ref id="B51-ijms-25-13418"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolli</surname><given-names>N.</given-names></name>
<name><surname>Avet-Loiseau</surname><given-names>H.</given-names></name>
<name><surname>Wedge</surname><given-names>D.C.</given-names></name>
<name><surname>Van Loo</surname><given-names>P.</given-names></name>
<name><surname>Alexandrov</surname><given-names>L.B.</given-names></name>
<name><surname>Martincorena</surname><given-names>I.</given-names></name>
<name><surname>Dawson</surname><given-names>K.J.</given-names></name>
<name><surname>Iorio</surname><given-names>F.</given-names></name>
<name><surname>Nik-Zainal</surname><given-names>S.</given-names></name>
<name><surname>Bignell</surname><given-names>G.R.</given-names></name>
<etal/>
</person-group><article-title>Heterogeneity of Genomic Evolution and Mutational Profiles in Multiple Myeloma</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>2997</fpage><pub-id pub-id-type="doi">10.1038/ncomms3997</pub-id><pub-id pub-id-type="pmid">24429703</pub-id>
</element-citation></ref><ref id="B52-ijms-25-13418"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>B.A.</given-names></name>
<name><surname>Boyle</surname><given-names>E.M.</given-names></name>
<name><surname>Wardell</surname><given-names>C.P.</given-names></name>
<name><surname>Murison</surname><given-names>A.</given-names></name>
<name><surname>Begum</surname><given-names>D.B.</given-names></name>
<name><surname>Dahir</surname><given-names>N.M.</given-names></name>
<name><surname>Proszek</surname><given-names>P.Z.</given-names></name>
<name><surname>Johnson</surname><given-names>D.C.</given-names></name>
<name><surname>Kaiser</surname><given-names>M.F.</given-names></name>
<name><surname>Melchor</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>3911</fpage><lpage>3920</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.1503</pub-id><pub-id pub-id-type="pmid">26282654</pub-id>
</element-citation></ref><ref id="B53-ijms-25-13418"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
</person-group><article-title>The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>745187</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.745187</pub-id><pub-id pub-id-type="pmid">34671561</pub-id>
</element-citation></ref><ref id="B54-ijms-25-13418"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piddock</surname><given-names>R.</given-names></name>
<name><surname>Bowles</surname><given-names>K.</given-names></name>
<name><surname>Rushworth</surname><given-names>S.</given-names></name>
</person-group><article-title>The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma</article-title><source>Cancers</source><year>2017</year><volume>9</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/cancers9040029</pub-id><pub-id pub-id-type="pmid">28350342</pub-id>
</element-citation></ref><ref id="B55-ijms-25-13418"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a-Ortiz</surname><given-names>A.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>Y.</given-names></name>
<name><surname>Encinas</surname><given-names>J.</given-names></name>
<name><surname>Maroto-Mart&#x000ed;n</surname><given-names>E.</given-names></name>
<name><surname>Castellano</surname><given-names>E.</given-names></name>
<name><surname>Teixid&#x000f3;</surname><given-names>J.</given-names></name>
<name><surname>Mart&#x000ed;nez-L&#x000f3;pez</surname><given-names>J.</given-names></name>
</person-group><article-title>The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13020217</pub-id><pub-id pub-id-type="pmid">33435306</pub-id>
</element-citation></ref><ref id="B56-ijms-25-13418"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hofmann</surname><given-names>C.</given-names></name>
<name><surname>St&#x000fc;hmer</surname><given-names>T.</given-names></name>
<name><surname>Schmiedl</surname><given-names>N.</given-names></name>
<name><surname>Wetzker</surname><given-names>R.</given-names></name>
<name><surname>Mottok</surname><given-names>A.</given-names></name>
<name><surname>Rosenwald</surname><given-names>A.</given-names></name>
<name><surname>Langer</surname><given-names>C.</given-names></name>
<name><surname>Zovko</surname><given-names>J.</given-names></name>
<name><surname>Chatterjee</surname><given-names>M.</given-names></name>
<name><surname>Einsele</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title><sc>PI</sc> 3K-dependent Multiple Myeloma Cell Survival Is Mediated by the <sc>PIK</sc> 3 <sc>CA</sc> Isoform</article-title><source>Br. J. Haematol.</source><year>2014</year><volume>166</volume><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1111/bjh.12920</pub-id><pub-id pub-id-type="pmid">24766330</pub-id>
</element-citation></ref><ref id="B57-ijms-25-13418"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azab</surname><given-names>F.</given-names></name>
<name><surname>Vali</surname><given-names>S.</given-names></name>
<name><surname>Abraham</surname><given-names>J.</given-names></name>
<name><surname>Potter</surname><given-names>N.</given-names></name>
<name><surname>Muz</surname><given-names>B.</given-names></name>
<name><surname>De La Puente</surname><given-names>P.</given-names></name>
<name><surname>Fiala</surname><given-names>M.</given-names></name>
<name><surname>Paasch</surname><given-names>J.</given-names></name>
<name><surname>Sultana</surname><given-names>Z.</given-names></name>
<name><surname>Tyagi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>PI3KCA Plays a Major Role in Multiple Myeloma and Its Inhibition with BYL719 Decreases Proliferation, Synergizes with Other Therapies and Overcomes Stroma-Induced Resistance</article-title><source>Br. J. Haematol.</source><year>2014</year><volume>165</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/bjh.12734</pub-id><pub-id pub-id-type="pmid">24405121</pub-id>
</element-citation></ref><ref id="B58-ijms-25-13418"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller</surname><given-names>L.</given-names></name>
<name><surname>Hainberger</surname><given-names>D.</given-names></name>
<name><surname>Stolz</surname><given-names>V.</given-names></name>
<name><surname>Hamminger</surname><given-names>P.</given-names></name>
<name><surname>Hassan</surname><given-names>H.</given-names></name>
<name><surname>Preglej</surname><given-names>T.</given-names></name>
<name><surname>Boucheron</surname><given-names>N.</given-names></name>
<name><surname>Sakaguchi</surname><given-names>S.</given-names></name>
<name><surname>Wiegers</surname><given-names>G.J.</given-names></name>
<name><surname>Villunger</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The Corepressor NCOR1 Regulates the Survival of Single-Positive Thymocytes</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>15928</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-15918-0</pub-id><pub-id pub-id-type="pmid">29162920</pub-id>
</element-citation></ref><ref id="B59-ijms-25-13418"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rinn</surname><given-names>J.L.</given-names></name>
<name><surname>Kertesz</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>J.K.</given-names></name>
<name><surname>Squazzo</surname><given-names>S.L.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Brugmann</surname><given-names>S.A.</given-names></name>
<name><surname>Goodnough</surname><given-names>L.H.</given-names></name>
<name><surname>Helms</surname><given-names>J.A.</given-names></name>
<name><surname>Farnham</surname><given-names>P.J.</given-names></name>
<name><surname>Segal</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>1311</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.05.022</pub-id><pub-id pub-id-type="pmid">17604720</pub-id>
</element-citation></ref><ref id="B60-ijms-25-13418"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berben</surname><given-names>L.</given-names></name>
<name><surname>Floris</surname><given-names>G.</given-names></name>
<name><surname>Wildiers</surname><given-names>H.</given-names></name>
<name><surname>Hatse</surname><given-names>S.</given-names></name>
</person-group><article-title>Cancer and Aging: Two Tightly Interconnected Biological Processes</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>1400</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13061400</pub-id><pub-id pub-id-type="pmid">33808654</pub-id>
</element-citation></ref><ref id="B61-ijms-25-13418"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urban</surname><given-names>V.S.</given-names></name>
<name><surname>Cegledi</surname><given-names>A.</given-names></name>
<name><surname>Mikala</surname><given-names>G.</given-names></name>
</person-group><article-title>Multiple Myeloma, a Quintessential Malignant Disease of Aging: A Geroscience Perspective on Pathogenesis and Treatment</article-title><source>GeroScience</source><year>2023</year><volume>45</volume><fpage>727</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1007/s11357-022-00698-x</pub-id><pub-id pub-id-type="pmid">36508077</pub-id>
</element-citation></ref><ref id="B62-ijms-25-13418"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laconi</surname><given-names>E.</given-names></name>
<name><surname>Marongiu</surname><given-names>F.</given-names></name>
<name><surname>DeGregori</surname><given-names>J.</given-names></name>
</person-group><article-title>Cancer as a Disease of Old Age: Changing Mutational and Microenvironmental Landscapes</article-title><source>Br. J. Cancer</source><year>2020</year><volume>122</volume><fpage>943</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0721-1</pub-id><pub-id pub-id-type="pmid">32042067</pub-id>
</element-citation></ref><ref id="B63-ijms-25-13418"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdallah</surname><given-names>N.</given-names></name>
<name><surname>Rajkumar</surname><given-names>S.V.</given-names></name>
<name><surname>Greipp</surname><given-names>P.</given-names></name>
<name><surname>Kapoor</surname><given-names>P.</given-names></name>
<name><surname>Gertz</surname><given-names>M.A.</given-names></name>
<name><surname>Dispenzieri</surname><given-names>A.</given-names></name>
<name><surname>Baughn</surname><given-names>L.B.</given-names></name>
<name><surname>Lacy</surname><given-names>M.Q.</given-names></name>
<name><surname>Hayman</surname><given-names>S.R.</given-names></name>
<name><surname>Buadi</surname><given-names>F.K.</given-names></name>
<etal/>
</person-group><article-title>Cytogenetic Abnormalities in Multiple Myeloma: Association with Disease Characteristics and Treatment Response</article-title><source>Blood Cancer J.</source><year>2020</year><volume>10</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1038/s41408-020-00348-5</pub-id><pub-id pub-id-type="pmid">32782240</pub-id>
</element-citation></ref><ref id="B64-ijms-25-13418"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grasedieck</surname><given-names>S.</given-names></name>
<name><surname>Panahi</surname><given-names>A.</given-names></name>
<name><surname>Jarvis</surname><given-names>M.C.</given-names></name>
<name><surname>Borzooee</surname><given-names>F.</given-names></name>
<name><surname>Harris</surname><given-names>R.S.</given-names></name>
<name><surname>Larijani</surname><given-names>M.</given-names></name>
<name><surname>Avet-Loiseau</surname><given-names>H.</given-names></name>
<name><surname>Samur</surname><given-names>M.</given-names></name>
<name><surname>Munshi</surname><given-names>N.</given-names></name>
<name><surname>Song</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Redefining High Risk Multiple Myeloma with an APOBEC/Inflammation-Based Classifier</article-title><source>Leukemia</source><year>2024</year><volume>38</volume><fpage>1172</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1038/s41375-024-02210-0</pub-id><pub-id pub-id-type="pmid">38461190</pub-id>
</element-citation></ref><ref id="B65-ijms-25-13418"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maura</surname><given-names>F.</given-names></name>
<name><surname>Rajanna</surname><given-names>A.R.</given-names></name>
<name><surname>Ziccheddu</surname><given-names>B.</given-names></name>
<name><surname>Poos</surname><given-names>A.M.</given-names></name>
<name><surname>Derkach</surname><given-names>A.</given-names></name>
<name><surname>Maclachlan</surname><given-names>K.</given-names></name>
<name><surname>Durante</surname><given-names>M.</given-names></name>
<name><surname>Diamond</surname><given-names>B.</given-names></name>
<name><surname>Papadimitriou</surname><given-names>M.</given-names></name>
<name><surname>Davies</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Genomic Classification and Individualized Prognosis in Multiple Myeloma</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>1229</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1200/JCO.23.01277</pub-id><pub-id pub-id-type="pmid">38194610</pub-id>
</element-citation></ref><ref id="B66-ijms-25-13418"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chng</surname><given-names>W.J.</given-names></name>
<name><surname>Gonzalez-Paz</surname><given-names>N.</given-names></name>
<name><surname>Price-Troska</surname><given-names>T.</given-names></name>
<name><surname>Jacobus</surname><given-names>S.</given-names></name>
<name><surname>Rajkumar</surname><given-names>S.V.</given-names></name>
<name><surname>Oken</surname><given-names>M.M.</given-names></name>
<name><surname>Kyle</surname><given-names>R.A.</given-names></name>
<name><surname>Henderson</surname><given-names>K.J.</given-names></name>
<name><surname>Van Wier</surname><given-names>S.</given-names></name>
<name><surname>Greipp</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Clinical and Biological Significance of RAS Mutations in Multiple Myeloma</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>2280</fpage><lpage>2284</lpage><pub-id pub-id-type="doi">10.1038/leu.2008.142</pub-id><pub-id pub-id-type="pmid">18528420</pub-id>
</element-citation></ref><ref id="B67-ijms-25-13418"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sacco</surname><given-names>A.</given-names></name>
<name><surname>Federico</surname><given-names>C.</given-names></name>
<name><surname>Todoerti</surname><given-names>K.</given-names></name>
<name><surname>Ziccheddu</surname><given-names>B.</given-names></name>
<name><surname>Palermo</surname><given-names>V.</given-names></name>
<name><surname>Giacomini</surname><given-names>A.</given-names></name>
<name><surname>Ravelli</surname><given-names>C.</given-names></name>
<name><surname>Maccarinelli</surname><given-names>F.</given-names></name>
<name><surname>Bianchi</surname><given-names>G.</given-names></name>
<name><surname>Belotti</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Specific Targeting of the KRAS Mutational Landscape in Myeloma as a Tool to Unveil the Elicited Antitumor Activity</article-title><source>Blood</source><year>2021</year><volume>138</volume><fpage>1705</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1182/blood.2020010572</pub-id><pub-id pub-id-type="pmid">34077955</pub-id>
</element-citation></ref><ref id="B68-ijms-25-13418"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giesen</surname><given-names>N.</given-names></name>
<name><surname>Paramasivam</surname><given-names>N.</given-names></name>
<name><surname>Toprak</surname><given-names>U.H.</given-names></name>
<name><surname>Huebschmann</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Uhrig</surname><given-names>S.</given-names></name>
<name><surname>Samur</surname><given-names>M.</given-names></name>
<name><surname>B&#x000e4;hr</surname><given-names>S.</given-names></name>
<name><surname>Fr&#x000f6;hlich</surname><given-names>M.</given-names></name>
<name><surname>Mughal</surname><given-names>S.S.</given-names></name>
<etal/>
</person-group><article-title>Comprehensive Genomic Analysis of Refractory Multiple Myeloma Reveals a Complex Mutational Landscape Associated with Drug Resistance and Novel Therapeutic Vulnerabilities</article-title><source>Haematologica</source><year>2022</year><volume>107</volume><fpage>1891</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.3324/haematol.2021.279360</pub-id><pub-id pub-id-type="pmid">35045690</pub-id>
</element-citation></ref><ref id="B69-ijms-25-13418"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>E.M.</given-names></name>
<name><surname>Rosenthal</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Farmer</surname><given-names>P.</given-names></name>
<name><surname>Rutherford</surname><given-names>M.</given-names></name>
<name><surname>Ashby</surname><given-names>C.</given-names></name>
<name><surname>Bauer</surname><given-names>M.</given-names></name>
<name><surname>Johnson</surname><given-names>S.K.</given-names></name>
<name><surname>Wardell</surname><given-names>C.P.</given-names></name>
<name><surname>Hoering</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>High-risk Transcriptional Profiles in Multiple Myeloma Are an Acquired Feature That Can Occur in Any Subtype and More Frequently with Each Subsequent Relapse</article-title><source>Br. J. Haematol.</source><year>2021</year><volume>195</volume><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1111/bjh.17670</pub-id><pub-id pub-id-type="pmid">34244996</pub-id>
</element-citation></ref><ref id="B70-ijms-25-13418"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Misund</surname><given-names>K.</given-names></name>
<name><surname>Hofste Op Bruinink</surname><given-names>D.</given-names></name>
<name><surname>Coward</surname><given-names>E.</given-names></name>
<name><surname>Hoogenboezem</surname><given-names>R.M.</given-names></name>
<name><surname>Rustad</surname><given-names>E.H.</given-names></name>
<name><surname>Sanders</surname><given-names>M.A.</given-names></name>
<name><surname>Rye</surname><given-names>M.</given-names></name>
<name><surname>Sponaas</surname><given-names>A.-M.</given-names></name>
<name><surname>Van Der Holt</surname><given-names>B.</given-names></name>
<name><surname>Zweegman</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Clonal Evolution after Treatment Pressure in Multiple Myeloma: Heterogenous Genomic Aberrations and Transcriptomic Convergence</article-title><source>Leukemia</source><year>2022</year><volume>36</volume><fpage>1887</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1038/s41375-022-01597-y</pub-id><pub-id pub-id-type="pmid">35643867</pub-id>
</element-citation></ref><ref id="B71-ijms-25-13418"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rustad</surname><given-names>E.H.</given-names></name>
<name><surname>Yellapantula</surname><given-names>V.</given-names></name>
<name><surname>Leongamornlert</surname><given-names>D.</given-names></name>
<name><surname>Bolli</surname><given-names>N.</given-names></name>
<name><surname>Ledergor</surname><given-names>G.</given-names></name>
<name><surname>Nadeu</surname><given-names>F.</given-names></name>
<name><surname>Angelopoulos</surname><given-names>N.</given-names></name>
<name><surname>Dawson</surname><given-names>K.J.</given-names></name>
<name><surname>Mitchell</surname><given-names>T.J.</given-names></name>
<name><surname>Osborne</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Timing the Initiation of Multiple Myeloma</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1917</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-15740-9</pub-id><pub-id pub-id-type="pmid">32317634</pub-id>
</element-citation></ref><ref id="B72-ijms-25-13418"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ewels</surname><given-names>P.A.</given-names></name>
<name><surname>Peltzer</surname><given-names>A.</given-names></name>
<name><surname>Fillinger</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>H.</given-names></name>
<name><surname>Alneberg</surname><given-names>J.</given-names></name>
<name><surname>Wilm</surname><given-names>A.</given-names></name>
<name><surname>Garcia</surname><given-names>M.U.</given-names></name>
<name><surname>Di Tommaso</surname><given-names>P.</given-names></name>
<name><surname>Nahnsen</surname><given-names>S.</given-names></name>
</person-group><article-title>The Nf-Core Framework for Community-Curated Bioinformatics Pipelines</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0439-x</pub-id><pub-id pub-id-type="pmid">32055031</pub-id>
</element-citation></ref><ref id="B73-ijms-25-13418"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>M.</given-names></name>
<name><surname>Juhos</surname><given-names>S.</given-names></name>
<name><surname>Larsson</surname><given-names>M.</given-names></name>
<name><surname>Olason</surname><given-names>P.I.</given-names></name>
<name><surname>Martin</surname><given-names>M.</given-names></name>
<name><surname>Eisfeldt</surname><given-names>J.</given-names></name>
<name><surname>DiLorenzo</surname><given-names>S.</given-names></name>
<name><surname>Sandgren</surname><given-names>J.</given-names></name>
<name><surname>D&#x000ed;az De St&#x000e5;hl</surname><given-names>T.</given-names></name>
<name><surname>Ewels</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Sarek: A Portable Workflow for Whole-Genome Sequencing Analysis of Germline and Somatic Variants</article-title><source>F1000Research</source><year>2020</year><volume>9</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.12688/f1000research.16665.2</pub-id><pub-id pub-id-type="pmid">32269765</pub-id>
</element-citation></ref><ref id="B74-ijms-25-13418"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
</person-group><article-title>fastp: An Ultra-Fast All-in-One FASTQ Preprocessor</article-title><source>Bioinformatics</source><year>2018</year><volume>34</volume><fpage>i884</fpage><lpage>i890</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty560</pub-id><pub-id pub-id-type="pmid">30423086</pub-id>
</element-citation></ref><ref id="B75-ijms-25-13418"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cibulskis</surname><given-names>K.</given-names></name>
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Carter</surname><given-names>S.L.</given-names></name>
<name><surname>Sivachenko</surname><given-names>A.</given-names></name>
<name><surname>Jaffe</surname><given-names>D.</given-names></name>
<name><surname>Sougnez</surname><given-names>C.</given-names></name>
<name><surname>Gabriel</surname><given-names>S.</given-names></name>
<name><surname>Meyerson</surname><given-names>M.</given-names></name>
<name><surname>Lander</surname><given-names>E.S.</given-names></name>
<name><surname>Getz</surname><given-names>G.</given-names></name>
</person-group><article-title>Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id><pub-id pub-id-type="pmid">23396013</pub-id>
</element-citation></ref><ref id="B76-ijms-25-13418"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McKenna</surname><given-names>A.</given-names></name>
<name><surname>Hanna</surname><given-names>M.</given-names></name>
<name><surname>Banks</surname><given-names>E.</given-names></name>
<name><surname>Sivachenko</surname><given-names>A.</given-names></name>
<name><surname>Cibulskis</surname><given-names>K.</given-names></name>
<name><surname>Kernytsky</surname><given-names>A.</given-names></name>
<name><surname>Garimella</surname><given-names>K.</given-names></name>
<name><surname>Altshuler</surname><given-names>D.</given-names></name>
<name><surname>Gabriel</surname><given-names>S.</given-names></name>
<name><surname>Daly</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The Genome Analysis Toolkit: A MapReduce Framework for Analyzing next-Generation DNA Sequencing Data</article-title><source>Genome Res.</source><year>2010</year><volume>20</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><pub-id pub-id-type="pmid">20644199</pub-id>
</element-citation></ref><ref id="B77-ijms-25-13418"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McLaren</surname><given-names>W.</given-names></name>
<name><surname>Gil</surname><given-names>L.</given-names></name>
<name><surname>Hunt</surname><given-names>S.E.</given-names></name>
<name><surname>Riat</surname><given-names>H.S.</given-names></name>
<name><surname>Ritchie</surname><given-names>G.R.S.</given-names></name>
<name><surname>Thormann</surname><given-names>A.</given-names></name>
<name><surname>Flicek</surname><given-names>P.</given-names></name>
<name><surname>Cunningham</surname><given-names>F.</given-names></name>
</person-group><article-title>The Ensembl Variant Effect Predictor</article-title><source>Genome Biol.</source><year>2016</year><volume>17</volume><elocation-id>122</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id>
</element-citation></ref><ref id="B78-ijms-25-13418"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rentzsch</surname><given-names>P.</given-names></name>
<name><surname>Witten</surname><given-names>D.</given-names></name>
<name><surname>Cooper</surname><given-names>G.M.</given-names></name>
<name><surname>Shendure</surname><given-names>J.</given-names></name>
<name><surname>Kircher</surname><given-names>M.</given-names></name>
</person-group><article-title>CADD: Predicting the Deleteriousness of Variants throughout the Human Genome</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D886</fpage><lpage>D894</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1016</pub-id><pub-id pub-id-type="pmid">30371827</pub-id>
</element-citation></ref><ref id="B79-ijms-25-13418"><label>79.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Kandoth</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Qwangmsk</surname></name>
<name><surname>Mattioni</surname><given-names>M.</given-names></name>
<name><surname>Struck</surname><given-names>A.</given-names></name>
<name><surname>Boursin</surname><given-names>Y.</given-names></name>
<name><surname>Penson</surname><given-names>A.</given-names></name>
<name><surname>Chavan</surname><given-names>S.</given-names></name>
</person-group><article-title>Mskcc/Vcf2maf: Vcf2maf v1.6.15</article-title><year>2017</year><comment>Available online: <ext-link xlink:href="https://zenodo.org/records/1127697" ext-link-type="uri">https://zenodo.org/records/1127697</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-21">(accessed on 21 February 2024)</date-in-citation></element-citation></ref><ref id="B80-ijms-25-13418"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shyr</surname><given-names>C.</given-names></name>
<name><surname>Tarailo-Graovac</surname><given-names>M.</given-names></name>
<name><surname>Gottlieb</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>J.J.</given-names></name>
<name><surname>Van Karnebeek</surname><given-names>C.</given-names></name>
<name><surname>Wasserman</surname><given-names>W.W.</given-names></name>
</person-group><article-title>FLAGS, Frequently Mutated Genes in Public Exomes</article-title><source>BMC Med. Genomics</source><year>2014</year><volume>7</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-014-0064-y</pub-id><pub-id pub-id-type="pmid">25466818</pub-id>
</element-citation></ref><ref id="B81-ijms-25-13418"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vogelstein</surname><given-names>B.</given-names></name>
<name><surname>Papadopoulos</surname><given-names>N.</given-names></name>
<name><surname>Velculescu</surname><given-names>V.E.</given-names></name>
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Diaz</surname><given-names>L.A.</given-names></name>
<name><surname>Kinzler</surname><given-names>K.W.</given-names></name>
</person-group><article-title>Cancer Genome Landscapes</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id>
</element-citation></ref><ref id="B82-ijms-25-13418"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Stojanov</surname><given-names>P.</given-names></name>
<name><surname>Polak</surname><given-names>P.</given-names></name>
<name><surname>Kryukov</surname><given-names>G.V.</given-names></name>
<name><surname>Cibulskis</surname><given-names>K.</given-names></name>
<name><surname>Sivachenko</surname><given-names>A.</given-names></name>
<name><surname>Carter</surname><given-names>S.L.</given-names></name>
<name><surname>Stewart</surname><given-names>C.</given-names></name>
<name><surname>Mermel</surname><given-names>C.H.</given-names></name>
<name><surname>Roberts</surname><given-names>S.A.</given-names></name>
<etal/>
</person-group><article-title>Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id>
</element-citation></ref><ref id="B83-ijms-25-13418"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rustad</surname><given-names>E.H.</given-names></name>
<name><surname>Nadeu</surname><given-names>F.</given-names></name>
<name><surname>Angelopoulos</surname><given-names>N.</given-names></name>
<name><surname>Ziccheddu</surname><given-names>B.</given-names></name>
<name><surname>Bolli</surname><given-names>N.</given-names></name>
<name><surname>Puente</surname><given-names>X.S.</given-names></name>
<name><surname>Campo</surname><given-names>E.</given-names></name>
<name><surname>Landgren</surname><given-names>O.</given-names></name>
<name><surname>Maura</surname><given-names>F.</given-names></name>
</person-group><article-title>Mmsig: A Fitting Approach to Accurately Identify Somatic Mutational Signatures in Hematological Malignancies</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><elocation-id>424</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-021-01938-0</pub-id><pub-id pub-id-type="pmid">33782531</pub-id>
</element-citation></ref><ref id="B84-ijms-25-13418"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Metzger</surname><given-names>P.</given-names></name>
<name><surname>Hess</surname><given-names>M.E.</given-names></name>
<name><surname>Blaumeiser</surname><given-names>A.</given-names></name>
<name><surname>Pauli</surname><given-names>T.</given-names></name>
<name><surname>Schipperges</surname><given-names>V.</given-names></name>
<name><surname>Mertes</surname><given-names>R.</given-names></name>
<name><surname>Christoph</surname><given-names>J.</given-names></name>
<name><surname>Unberath</surname><given-names>P.</given-names></name>
<name><surname>Reimer</surname><given-names>N.</given-names></name>
<name><surname>Scheible</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>MIRACUM-Pipe: An Adaptable Pipeline for Next-Generation Sequencing Analysis, Reporting, and Visualization for Clinical Decision Making</article-title><source>Cancers</source><year>2023</year><volume>15</volume><elocation-id>3456</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15133456</pub-id><pub-id pub-id-type="pmid">37444566</pub-id>
</element-citation></ref><ref id="B85-ijms-25-13418"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wickham</surname><given-names>H.</given-names></name>
<name><surname>Averick</surname><given-names>M.</given-names></name>
<name><surname>Bryan</surname><given-names>J.</given-names></name>
<name><surname>Chang</surname><given-names>W.</given-names></name>
<name><surname>McGowan</surname><given-names>L.</given-names></name>
<name><surname>Fran&#x000e7;ois</surname><given-names>R.</given-names></name>
<name><surname>Grolemund</surname><given-names>G.</given-names></name>
<name><surname>Hayes</surname><given-names>A.</given-names></name>
<name><surname>Henry</surname><given-names>L.</given-names></name>
<name><surname>Hester</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Welcome to the Tidyverse</article-title><source>J. Open Source Softw.</source><year>2019</year><volume>4</volume><fpage>1686</fpage><pub-id pub-id-type="doi">10.21105/joss.01686</pub-id></element-citation></ref><ref id="B86-ijms-25-13418"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mayakonda</surname><given-names>A.</given-names></name>
<name><surname>Lin</surname><given-names>D.-C.</given-names></name>
<name><surname>Assenov</surname><given-names>Y.</given-names></name>
<name><surname>Plass</surname><given-names>C.</given-names></name>
<name><surname>Koeffler</surname><given-names>H.P.</given-names></name>
</person-group><article-title>Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer</article-title><source>Genome Res.</source><year>2018</year><volume>28</volume><fpage>1747</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1101/gr.239244.118</pub-id><pub-id pub-id-type="pmid">30341162</pub-id>
</element-citation></ref><ref id="B87-ijms-25-13418"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Denz</surname><given-names>R.</given-names></name>
<name><surname>Timmesfeld</surname><given-names>N.</given-names></name>
</person-group><article-title>Visualizing the (Causal) Effect of a Continuous Variable on a Time-To-Event Outcome</article-title><source>Epidemiology</source><year>2023</year><volume>34</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1097/EDE.0000000000001630</pub-id><pub-id pub-id-type="pmid">37462467</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-25-13418-f001"><label>Figure 1</label><caption><p>Oncoplot displaying potential driver genes inferred by MutSigCV (<italic toggle="yes">p</italic> &#x0003c; 0.001, <italic toggle="yes">n</italic> = 35). Bar plots refer to individual tumor burden (upper bar plot in mutations per megabase), &#x02212;<italic toggle="yes">log</italic><sub>10</sub>
<italic toggle="yes">p</italic> values retrieved from MutSigCV (<bold>left</bold>), and the number of samples harboring mutations in a given gene (<bold>right</bold>). Different classes of mutations are color-coded, and additional covariates are shown below (Revised International Scoring System (R-ISS)).</p></caption><graphic xlink:href="ijms-25-13418-g001" position="float"/></fig><fig position="float" id="ijms-25-13418-f002"><label>Figure 2</label><caption><p>Oncogenic pathways are affected by mutations found in the cohort. (<bold>A</bold>) Heatmap showing the individual sample contributions to affected pathways and the frequency of affected pathways in percentage; (<bold>B</bold>) bar graphs showing the fraction of genes mutated in a particular pathway.</p></caption><graphic xlink:href="ijms-25-13418-g002" position="float"/></fig><fig position="float" id="ijms-25-13418-f003"><label>Figure 3</label><caption><p>Somatic interactions between mutated genes selected by MutSigCV (<italic toggle="yes">p</italic> &#x0003c; 0.001). Higher co-occurrence of gene mutations is shown in red, while blue refers to mutually exclusive mutations. Gene names on the left and upper side with the number of affected patients in the cohort; <italic toggle="yes">p</italic>-values for statistical significance marked with (<italic toggle="yes">p</italic> &#x0003c; 0.05) or * (<italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="ijms-25-13418-g003" position="float"/></fig><fig position="float" id="ijms-25-13418-f004"><label>Figure 4</label><caption><p>COSMIC single-base substitution (SBS) signatures found in the analyzed cohort. Bar graphs show the color-coded proportion of somatic signatures per individual sample.</p></caption><graphic xlink:href="ijms-25-13418-g004" position="float"/></fig><fig position="float" id="ijms-25-13418-f005"><label>Figure 5</label><caption><p>Kaplan&#x02013;Meier curve differences in progression-free survival with mutational status of <italic toggle="yes">KRAS</italic>.</p></caption><graphic xlink:href="ijms-25-13418-g005" position="float"/></fig><table-wrap position="float" id="ijms-25-13418-t001"><object-id pub-id-type="pii">ijms-25-13418-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical and cytogenetic characteristics of the study cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size (N)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">35</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sex:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/35 (42.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20/35 (57.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median age at diagnosis [years]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.8 (Range: 43&#x02013;85)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma cell bone marrow infiltration (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (Range: 12&#x02013;80)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-ISS-Score:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-ISS 1 <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10/35 (28.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-ISS 2 <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/35 (48.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R-ISS 3 <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/35 (22.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytogenetics: </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">del17p <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/30 (10.0) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translocation t(4;14) <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/30 (0) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translocation t(14;16) <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/30 (3.3) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translocation t(14;20) <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/30 (3.3) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initial 1p, 1q alteration <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8/30 (26.7) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Translocation t(11;14) <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4/30 (13.3) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hyperdiploidy <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/30 (43.3) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment ** <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/31 (19.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VRD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/31 (19.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VCD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9/31 (29.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dara-VTD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/31 (3.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dara-VD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/31 (3.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/31 (9.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/31 (9.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E-KRD <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/31 (6.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autologous transplantation <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/31 (54.8) **</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relapse <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/35 (14.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5/35 (14.3)</td></tr></tbody></table><table-wrap-foot><fn><p>* 5 Patients with unknown cytogenetic diagnosis; ** 4 Patients with missing clinical data; R-ISS: Revised International Staging System; Dexamethasone (D), Bortezomib (V (Velcade)), Lenalidomide (R (Revlimid)), Cyclophosphamide (C), Daratumumab (Dara), Thalidomide (T), Carfilzomib (K), Elotuzumab (E).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-25-13418-t002"><object-id pub-id-type="pii">ijms-25-13418-t002_Table 2</object-id><label>Table 2</label><caption><p>Genes with significant association with SBS signatures.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Signature</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Signature</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations related to cell aging (i.e., clock-like)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations related to cell aging (i.e., clock-like)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">GPNMB</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0412</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resulting from APOBEC cytidine deaminase activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resulting from APOBEC cytidine deaminase activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">TYW1</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0340</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown etiology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">GPNMP</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0066</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-canonical genome-wide action of AID (nc-AID)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">NCOR1</italic>
<break/>
<italic toggle="yes">OR51G1</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0054 <break/> 0.0405</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Related to DNA damage from reactive oxygen species</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">PIK3CA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0179</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SBS-MM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutational footprint of melphalan therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap></floats-group></article>